Biophysical investigation of the ligand-induced assembling of the human type I interferon receptor by Lamken, Peter
 
Biophysical Investigation of the Ligand-induced 
Assembling of the human Type I Interferon Receptor 
 
Dissertation 
zur Erlangung des Doktorgrades 
der Naturwissenschaften 
 
vorgelegt beim Fachbereich 
Chemische und Pharmazeutische Wissenschaften 
der Johann Wolfgang Goethe-Universität in Frankfurt am Main 
 
 
von 
Peter Lamken 
aus Kelsterbach am Main 
 
 
 
Frankfurt, 2005 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
vom Fachbereich Chemische und Pharmazeutische Wissenschaften der 
Johann Wolfgang Goethe-Universität als Dissertation angenommen. 
 
 
Dekan:    
 
1. Gutachter:  Dr. Jacob Piehler 
2. Gutachter:  Prof. Dr. Robert Tampé 
 
Datum der Disputation: 
 
 
 
 Index 
Index 
 
 
1  Deutsche Zusammenfassung........................................................................................1
 
2  Summary.........................................................................................................................6 
 
3  Introduction.....................................................................................................................7 
3.1  Cytokines and cytokine receptors.............................................................................7 
3.1.1  Overview of cytokines and cytokine receptors..................................................7 
3.1.2  Extracellular structure of type I cytokine receptors...........................................9 
3.1.3  Type II cytokine receptors...............................................................................11 
3.1.4  Mechanisms of cytokine receptor signaling....................................................13 
3.1.5  Type I cytokine receptor signaling ..................................................................13 
3.1.6  Type II cytokine receptor signaling .................................................................15 
3.2  Type I interferons....................................................................................................16 
3.3  The human type I interferon receptor ifnar .............................................................18 
3.3.1  Overview.........................................................................................................18 
3.3.2  Signal transduction induced by IFN mediated receptor assembly..................19 
3.3.3  Structure-function relationships ......................................................................20 
3.4  Objectives...............................................................................................................24 
3.5  Strategy ..................................................................................................................25 
3.5.1  Ifnar1-EC expression in quantitative amounts................................................25 
3.5.2  Ifnar1-EC sub-fragments and mutants............................................................27 
3.5.3  Detection techniques ......................................................................................29 
3.5.4  Immobilization techniques ..............................................................................31 
 
4  Materials........................................................................................................................33 
4.1  Chemicals...............................................................................................................33 
4.2  Cells, Media and Transfection material ..................................................................34 
4.3  Enzymes, plasmids and reaction buffers................................................................34 
4.4  Oligonucleotides for cloning....................................................................................35 
4.5  Oligonucleotides for mutagenesis...........................................................................36 
4.6  Chromatography equipment...................................................................................36 
4.7  Buffers and solutions for purification and binding assays.......................................37 
 
5  Methods.........................................................................................................................38 
5.1  Molecular Biology ...................................................................................................38 
5.1.1  Overview.........................................................................................................38 
5.1.2  Polymerase Chain Reaction ...........................................................................38 
5.1.3  DNA preparation.............................................................................................39 
5.1.4  Restriction of DNA ..........................................................................................39 
5.1.5  Ligation...........................................................................................................39 
5.1.6  Transformation................................................................................................39 
5.1.7  Site Directed Mutagenesis..............................................................................39 
5.1.8  Oligonucleotide Insertion ................................................................................40 
5.1.9  Sequencing.....................................................................................................42 
5.2  Insect cell culture....................................................................................................42 
5.2.1  Monolayer culture of Sf9 cells.........................................................................42 
5.2.2  Shaking culture of Sf9 cells ............................................................................42 
5.2.3  Co-transfection of Sf9 cells.............................................................................42 
5.2.4  Infection cultures for protein production..........................................................43 
 Index 
5.3  Protein purification and characterization.................................................................44 
5.3.1  Overview of proteins.......................................................................................44 
5.3.2  Immobilized metal chelate affinity chromatography (IMAC)............................44 
5.3.3  Size exclusion chromatography (SEC)...........................................................44 
5.3.4  Protein concentration......................................................................................45 
5.3.5  Protein concentration determination...............................................................45 
5.3.6  Deglycosylation...............................................................................................45 
5.3.7  Western-Blot...................................................................................................46 
5.3.8  CD-Spectroscopy............................................................................................46 
5.4  Protein interactions on surfaces .............................................................................47 
5.4.1  Detection system ............................................................................................47 
5.4.2  Vesicle preparation and bilayer fusion............................................................47 
5.4.3  Protein interaction experiments ......................................................................48 
 
6  Results...........................................................................................................................49 
6.1  Protein Biochemistry...............................................................................................49 
6.1.1  Purification of ifnar1-EC and sub-fragments...................................................49 
6.1.2  Protein deglycosylation...................................................................................52 
6.1.3  Further biochemical characterization..............................................................53 
6.2  Dissection of interferon receptor assembling..........................................................56 
6.2.1  Stoichiometry of the IFN receptor complex in solution....................................56 
6.2.2  Interaction of ifnar2-EC with IFNα2 and IFNβ on solid support ......................58 
6.2.3  Interaction of IFNs with ifnar1-EC...................................................................61 
6.2.4  Interaction of ifnar1-EC sub-fragments with IFNα2 and IFNβ.........................65 
6.2.5  IFNα2 and IFNβ compete for the same binding site on ifnar1-EC..................69 
6.2.6  Identification of residues critical for interferon binding....................................71 
6.3  Complex formation on lipid bilayers........................................................................74 
6.3.1  Introduction.....................................................................................................74 
6.3.2  Interaction of ifnar1-EC and ifnar2-EC on fluid support..................................74 
6.3.3  Complex stability depends on receptor surface concentration .......................79 
6.3.4  Dynamic exchange processes on the ternary complex ..................................81 
6.3.5  Complex formation of ifnar1-EC sub-fragments on lipid bilayers....................83 
6.3.6  Understanding of the role of SD4 in ternary complex assembling..................85 
6.3.7  Single particle analysis ...................................................................................88 
 
7  Discussion ....................................................................................................................89 
7.1  Expression, purification and biochemical characterization.....................................89 
7.2  Dissection of interferon receptor assembling..........................................................90 
7.3  Complex formation on lipid bilayers........................................................................92 
7.4  Outlook ...................................................................................................................95 
 
8  Abbreviations................................................................................................................96 
 
9  References....................................................................................................................98 
 
10  Publications................................................................................................................108 
 
 
 
 
 Deutsche Zusammenfassung 
1 Deutsche  Zusammenfassung 
Die biochemischen und zellbiologischen Mechanismen der interzellulären 
Kommunikation über Zellbotenstoffe, die Zytokine, spielen eine bedeutende Rolle sowohl in 
der grundlagenorientierten als auch in der biomedizinischen Forschung. Eine Gruppe der 
Zytokine, die Typ I Interferone (IFN), stellt aufgrund ihrer antiviralen, antiproliferativen, 
immunmodulatorischen und antiinflammatorischen Aktivitäten eine wichtige Komponente des 
angeborenen Immunsystems dar. Von besonderer Bedeutung ist ihre Rolle bei der 
frühzeitigen Abwehr von Viren, in der sie die erste Antwort in einer Reihe von antiviralen 
Mechanismen bilden. Bisher sind 16 humane Typ I Interferone bekannt (13 IFNα, β, ε und ω). 
Abhängig vom Zell- und Gewebetyp kann ein Interferon zu unterschiedlichen zellulären 
Aktivitäten führen, was als pleiotroper Effekt bezeichnet wird. 
Zentrales Element der Interferon-vermittelten Signaltransduktion ist der IFN Rezeptor 
ifnar, welcher sich aus den beiden Transmembranproteinen ifnar1 und ifnar2 zusammensetzt 
und zur Familie der Klasse II Zytokin Rezeptoren gehört. Dieser Rezeptor fungiert als 
Verbindungselement zwischen extrazellulärem Milieu und dem Zytoplasma. Alle bekannten 
IFN rekrutieren ifnar, jedoch führen sie in Abhängigkeit vom jeweiligen Interferon und vom 
zellulären Kontext zu unterschiedlicher Akzentuierung der aktivierten Signalwege, was als 
differentielle Signalaktivierung bezeichnet wird. Dies lässt vermuten, dass die differentielle 
Signalaktivierung in der Erkennung der IFN durch den Rezeptor codiert ist.  
Ziel dieser Arbeit war es, die Ligand-induzierte Rezeptorassemblierung 
biophysikalisch zu untersuchen und damit die molekularen Prinzipien der differentiellen 
Signalaktivierung  in vitro zu erforschen. Als Modellsystem dienten die extrazellulären 
Domänen ifnar1-EC und ifnar2-EC, welche für die Ligandenbindung verantwortlich sind. Die 
hochaffine Interaktion zwischen ifnar2-EC und IFNα2 ist detailliert in vitro untersucht worden, 
jedoch war nur wenig über ifnar1 bekannt. Da vermutet wird, dass die niedrigaffine 
Komponente ifnar1 für die differentielle Signalaktivierung verantwortlich ist, steht die 
extrazelluläre Domäne ifnar1-EC im Fokus dieser Arbeit. Die folgenden Aspekte lagen dabei 
im Zentrum des Interesses: 
¾  Thermodynamik, Kinetik und Stöchiometrie der Einzelinteraktionen zwischen 
allen involvierten Proteinen: ifnar1-EC, ifnar2-EC und Interferon 
¾  Charakterisierung der Bindungsstelle für verschiedene Liganden auf ifnar1-EC 
¾ Stabilität, Dynamik und Stöchiometrie des Signalkomplexes hinsichtlich 
verschiedener Liganden 
¾  Strukturelle Organisation von ifnar1-EC im Signalkomplex 
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Ifnar1-EC musste zunächst in quantitativen Mengen hergestellt werden, um die 
Etablierung eines Bindungsassays zu ermöglichen. Die heterologe, periplasmatische 
Expression in E. coli führte nur zu geringen Ausbeuten (50 µg/l), und auch andere 
Expressionsstrategien lieferten keine nachweisbaren Mengen an monomerem Protein. Aus 
diesem Grund wurde die Expression in Sf9 Insektenzellen eingesetzt. Mittels homologer 
Rekombination wurde das Gen ifnar1-EC mit einem C-terminalen Deca-Histidin-tag in das 
Genom des Baculovirus integriert. Von diesen Viren infizierte Sf9 Zellen exprimierten 
ifnar1-EC und sezernierten es in das Medium, was zugleich den ersten Reinigungsschritt 
darstellte. Durch Metall-Affinitätschromatographie wurde ifnar1-EC aus dem Medium 
extrahiert und von anderen Proteinen abgetrennt. Im abschließenden Reinigungsschritt, der 
Gelfiltration, wurden dann Aggregate und niedermolekulare Kontaminationen entfernt und 
gleichzeitig sichergestellt, dass ifnar1-EC als Monomer vorliegt. Die Ausbeute für lag bei ca. 
10 mg pro Liter Zellkultur. Es zeigte sich, dass ifnar1-EC glykosyliert war, was durch 
Deglykosylierungsexperimente mittels PNGaseF bestätigt werden konnte. Die 
Glykosylierung erwies sich als protein-stabilisierender Faktor, der die Handhabung und 
Lagerung wesentlich erleichterte. Ebenso konnte die Ausbildung von Disulfidbrücken, welche 
bei Stabilität und Funktion eine wichtige Rolle spielen, nachgewiesen werden. 
Um Stöchiometrie und Kinetik der Rezeptor-Ligand-Interaktionen mittels 
Reflektometrischer Interferenzspektroskopie (RIfS) zu untersuchen, wurden ifnar1-EC und 
ifnar2-EC mit Hilfe des Deca-Histidin-tags gerichtet und funktional auf Oberflächen 
immobilisiert. Die Immobilisierung wurde wie bei der Reinigung über eine Metall-Chelator 
Interaktion gewährleistet. Dazu wurden multivalente Chelatoren auf einer modifizierten 
Glasoberfläche kovalent gebunden und Ni
2+ über 4 Koordinationsstellen komplexiert. Der 
Deca-Histidin-tag konnte darauf über die freien Koordinationsstellen des Ni
2+ binden und so 
das Protein stabil auf der Oberfläche verankert werden.  
Zur Untersuchung der Einzelinteraktionen wurde stets eine Untereinheit immobilisiert 
und anschließend der Assoziations- und Dissoziationsprozess für IFNα2 und IFNβ 
untersucht. Alle Interaktionen zwischen ifnar1-EC bzw. ifnar2-EC und IFNα2/β wiesen eine 
1:1 Stöchiometrie auf. Es zeigten sich jedoch sowohl zwischen den Interferonen als auch 
zwischen den Rezeptoren große Unterschiede in der Affinität. Für ifnar2-EC wurde eine 
Dissoziationskonstante von 3 nM für IFNα2 bestimmt, wohingegen IFNβ erheblich stärker 
bindet (KD < 0.1 nM). Ifnar1-EC bindet sowohl IFNα2 (KD = 5 ± 2 µM) als auch IFNβ (KD = 50 
± 30 nM) etwa drei Größenordnungen schwächer als ifnar2-EC. Im Falle von IFNα2 wurde 
eine transiente Interaktion mit einer Lebensdauer ~ 1 s gemessen. Eine kooperative Bindung 
in Anwesenheit von ifnar2-EC ohne His-tag konnte weder für IFNα2 noch für IFNβ gezeigt 
werden. Dieses Ergebnis wurde durch die Beobachtung gestützt, dass keinerlei Interaktion 
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zwischen den beiden Rezeptoren nachgewiesen werden konnte. Eine Interaktion zwischen 
ifnar1-EC und ifnar2-EC konnte somit ausgeschlossen werden.  
Um die Bindungsstelle(n) für IFNα2 und IFNβ genauer zu charakterisieren, wurden 
verschiedene Konstrukte von ifnar1-EC hergestellt, die eine unterschiedliche Anzahl an 
Immunglobulin-ähnlichen Sub-domänen (SD) beinhalteten. Da ifnar1-EC vier solcher 
Domänen mit einer Größe von je ~100 Aminosäuren enthält (SD1234), wurden die folgenden 
Sub-Fragmente anhand der Domänenanordnung und Stellung des His-tags benannt: H10-
SD12, SD34-H10, SD123-H10, H10-SD123 und SD234-H10. Alle Sub-Fragmente ließen 
sich in vergleichbaren Ausbeuten wie der Wildtyp exprimieren und reinigen. Zudem wurde 
ein ifnar1-EC-Konstrukt mit N- und C-terminalem His-tag (SD1234-DT) hergestellt, welches 
eine doppelte Verankerung mit der Membran simulieren sollte. Um sicherzustellen, dass alle 
Konstrukte korrekt gefaltet waren, wurde die Sekundärstruktur mittels CD-Spektroskopie 
untersucht. Wie erwartet wiesen alle Proteine einen hohen Anteil an β-Faltblättern auf 
(~  80  %), was ein typisches Strukturmerkmal aller extrazellulären Domänen von Klasse I 
Zytokinrezeptoren darstellt. Bei der biochemischen Charakterisierung mittels analytischer 
Gelfiltration und SDS-PAGE fiel auf, dass H10-SD123 und SD234-H10 trotz etwa gleichem 
Molekulargewichts ein unterschiedliches Laufverhalten aufwiesen, wobei H10-SD123 zu 
einem höheren Molekulargewicht verschoben wurde. Diese auch nach Deglykosylierung 
reproduzierbare Verschiebung indiziert eine eher gestreckte Anordnung der drei N-
terminalen gegenüber den drei C-terminalen Domänen und damit einen nicht symmetrischen 
Aufbau von ifnar1-EC. In Bindungsexperimenten zeigte sich, dass nur SD123-H10 und H10-
SD123 Bindungsaktivität für IFNα2 und IFNβ aufwiesen, alle anderen Sub-Fragmente 
zeigten keinerlei Bindung im detektierbaren Konzentrationsbereich. Auch eine 
Rekonstruktion der Bindungsstelle durch Co-Immobilisierung von H10-SD12 und SD34-H10 
konnte nicht erreicht werden. Hieraus lässt sich folgern, dass für die Liganden-Bindung alle 
drei N-terminalen Domänen in einem Polypeptidstrang vorliegen müssen. Hinsichtlich der 
Bindungsaffinität waren keine signifikanten Unterschiede zwischen ifnar1-EC, SD1234-DT 
und H10-SD123 nachweisbar. Um mögliche Unterschiede in der Bindungsregion auf 
ifnar1-EC bzw. SD123 für IFNα2 und IFNβ nachzuweisen, wurden Kompetitionsexperimente 
mit Fluoreszenz-markiertem IFNα2 durchgeführt. Hierbei zeigte sich, dass IFNα2 und 
IFNβ, wie bei ifnar2-EC, um die gleiche Bindungsregion auf ifnar1-EC konkurrieren und damit 
auch in dieser Hinsicht kein Unterschied zwischen diesen beiden Interferonen in der 
Rekrutierung von ifnar1-EC besteht.  
Zur genaueren Charakterisierung der Liganden-Bindungsstelle wurden mehrere 
Mutationen auf allen 4 Sub-Domänen auf ifnar1-EC eingeführt. Diese Mutanten, von denen 
sich der größte Teil wie der Wildtyp exprimieren und reinigen ließ, wurden hinsichtlich ihrer 
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Bindung an IFNα2 und IFNβ untersucht. Anstelle von IFNα2wt wurde eine höher affine 
Mutante (IFNα2-HEQ) verwendet, die ähnliche Bindungseigenschaften wie IFNβ aufwies, 
jedoch leichter zu handhaben war. Es wurden mehrere Reste identifiziert, die die 
Bindungsaffinität sowohl für IFNα2-HEQ als auch für IFNβ um eine Größenordnung oder 
mehr reduzierten. Auf SD1 wurde eine Aminosäure (Y70), auf SD2 vier (E111, K113, W129 
und F136) und auf SD3 auch eine Aminosäure (K251) identifiziert. Auf SD4 konnte keine 
Mutation erzeugt werden, welche die Bindungsaffinität reduziert. Diese Ergebnisse 
untermauerten die Beobachtungen mit den Sub-Fragmenten und stärkten die Vermutung, 
dass die 3 N-terminalen Domänen für die Ligandenbindung und SD4 für die Komplexbildung 
verantwortlich sind.  
Um die Bildung des Signalkomplexes durch IFN Zugabe zu untersuchen, wurden 
ifnar1-EC und ifnar2-EC auf einer Chelator-Lipid-Oberfläche co-immobilisiert. Die 
Verwendung einer Lipid-Doppelschicht ermöglichte laterale Mobilität. Dies wurde durch 
entsprechende FRAP-Messungen mit Fluoreszenz-markiertem ifnar2 bestätigt. Nach Zugabe 
von IFNα2 bildete sich ein stabiler Komplex mit einer 1:1:1 Stöchiometrie. Diese 
Stöchiometrie konnte in Lösung mittels Gelfiltration bestätigt werden. Durch Verwendung von 
IFNα2- und ifnar2-EC-Mutanten mit niedrigerer Affinität wurde gezeigt, dass die Stabilität der 
IFNα2-ifnar2-EC Interaktion durch ifnar1-EC um den Faktor 200 gesteigert wurde. 
Kontrollexperimente auf Glasoberflächen zeigten, dass die Mobilität der 
Rezeptorkomponenten, wie sie in Lipid-Doppelschichten vorliegt, für die Bildung eines 
solchen stabilen Komplexes essentiell ist. Es stellte sich nun die Frage, ob der ternäre 
Komplex statisch oder dynamisch stabilisiert wurde. Um diese Frage zu beantworten, wurde 
die Oberflächenkonzentration von ifnar1-EC und ifnar2-EC reduziert und die Bindung von 
Fluoreszenz-markiertem IFNα2 S136C mittels TIRFS (Totalinterne Reflektions-Fluoreszenz-
Spektroskopie) aufgrund erheblich höherer Sensitivität gegenüber RIfS detektiert. Hierbei 
zeigte sich mit abnehmender Rezeptor-Oberflächenkonzentration eine zunehmende 
Dissoziationsratenkonstante, was einen ersten Hinweis auf eine dynamische Stabilisierung 
darstellte. Diese Vermutung wurde durch Austauschexperimente mit unmarkiertem IFNα2 
bestätigt. Zudem wurde durch Injektion von löslichem ifnar2-EC gezeigt, dass die Stabilität 
des ternären Komplexes kein Diffusions-basiertes Rückbindungsphänomen aufgrund von 
Diffusionen an Grenzflächen ist. 
Diese Ergebnisse lassen sich durch ein zweistufiges Bindungsmodell erklären. 
Zunächst wird der Ligand an die hochaffine Rezeptorkomponente ifnar2 gebunden und bildet 
damit einen binären Komplex (beschrieben durch K1). Im zweiten Schritt, welcher in der 
Membranebene stattfindet (beschrieben durch K2), führt die Bindung von ifnar1 über die 
direkte Interaktion mit IFN zur Bildung des ternären Komplexes. Die Komplexbildung und die 
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Dissoziation lassen sich durch die 2-dimensionale Assoziationsratenkonstante (k2) bzw. die 
Dissoziationsratenkonstante (k-2) der IFN/ifnar1-EC-Interaktion auf der Membran 
beschreiben. Da unterschiedliche Affinitäten für IFNα2 und IFNβ bestimmt wurden, wird klar, 
dass die Stabilität des Komplexes und damit die Effizienz der Signalaktivierung von der 
Dissoziationsratenkonstante der IFN/ifnar1-EC-Interaktion abhängen. Die differentielle 
Signalaktivierung durch verschiedene Interferone ließe sich somit durch die 
unterschiedlichen Dissoziationsratenkonstanten erklären. Ebenso wird klar, dass die 
Komplexbildung und damit k2 zum einen von der Rezeptoroberflächenkonzentration, zum 
anderen von der Affinität von ifnar1 mit dem binären Komplex abhängen. Unterschiedliche 
Rezeptoroberflächenkonzentrationen auf verschiedenen Zelltypen könnten erklären, warum 
verschiedene Zelltypen unterschiedlich auf das gleiche IFN reagieren (pleitroper Effekt). 
Um diesen Prozess der Komplexbildung genauer zu untersuchen, wurde die 
Rezeptorassemblierung mit verschiedenen ifnar1-Varianten auf Lipid-Doppelschichten 
untersucht. SD123-H10, H10-SD123 und SD1234-DT waren bei hohen 
Oberflächenkonzentrationen in der Lage, einen stabilen ternären Komplex zu bilden. Bei 
niedrigeren Rezeptor-Oberflächenkonzentrationen jedoch waren deutliche Unterschiede in 
der Komplexstabilität zu beobachten. C-terminal und doppelt verankerter ifnar1-EC zeigten 
keinen Unterschied, jedoch wies SD123 unabhängig von der Position des His-tags eine 
deutlich gesteigerte Dissoziation auf. Offensichtlich erhöht SD4 die Wahrscheinlichkeit einer 
erfolgreichen Komplexbildung, was die reduzierte Komplexstabilität bei Entfernung dieser 
Domäne erklären könnte. Diese Vermutung wurde durch Bindungsexperimente auf Zellen 
bestätigt, in denen ausschließlich ifnar1-EC zu messbarer Bindung führte. Um den Einfluss 
der Orientierung von SD4 auf die Komplexbildung genauer zu untersuchen, wurden weitere 
Konstrukte hergestellt. Zum einen wurde ifnar1-EC mit einem N-terminalen His-tag 
ausgestattet (H10-SD1234), zum anderen wurde SD4 von ifnar1 durch SD2 des IFNλ-
Rezeptors (SD123-LRD2-H10) bzw. des IL-10 Rezeptors (SD123-IL-10R2D2) ersetzt. 
Sowohl die N-terminale Verankerung als auch der Austausch von SD4 zeigte gegenüber der 
C-terminalen Immobilisierung eine reduzierte Komplexstabilität ähnlich wie SD123. Hieraus 
lässt sich der Schluss ziehen, dass SD4 offensichtlich für die optimale Orientierung der 
Ligandenbindungsstelle von ifnar1 verantwortlich ist und damit eine essentielle Rolle bei der 
Assemblierung des ternären Komlexes spielt.  
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2 Summary 
Type I interferons (IFNs) elicit antiviral, antiproliferative and immunmodulatory 
responses through binding to a shared receptor consisting of the transmembrane proteins 
ifnar1 and ifnar2. Differential signaling by different interferons suggests different modes of 
receptor engagement. In this work the ligand-induced receptor assembly of the extracellular 
domains (EC) of ifnar1 and 2 was investigated in terms of thermodynamics, kinetics, 
stoichiometry and structural organization. An efficient expression and purification strategy for 
ifnar1-EC using Sf9 insect cells was established. Using reflectance interference 
spectroscopy (RIfS) the interactions between IFNα2/β and ifnar1-EC and ifnar2-EC were 
studied in order to understand the individual contributions within the ternary complex. Low 
affinity for the IFNα2/ifnar1-EC interaction (KD ~ 5  µM) in comparison to high affinity for 
IFNα2/ifnar2-EC (KD ~ 3 nM) was observed. Substantially tighter binding of IFNβ to both 
ifnar2-EC and ifnar1-EC compared to IFNα2 was observed. For neither IFNα2 nor IFNβ any 
cooperative effect of ifnar2-EC on IFN-ifnar1-EC interaction was detected. Thus stem-stem 
interactions between the extracellular domains do not seem to play a role for ternary complex 
formation. Based on this analysis a two-step binding mechanism was suggested. In order to 
identify differences between different IFNs in ligand recognition, ifnar1-EC was dissected into 
sub-fragments containing different potential Ig-like domains. Appropriate folding of these 
proteins was confirmed by CD-spectroscopy. Surprisingly, only fragments containing all three 
N-terminal Ig-like domains were active in terms of ligand binding. Additionally it was 
demonstrated that IFNα2 and IFNβ compete for the same binding site and mainly the same 
residues. To investigate the mechanism of complex formation, ligand-induced cross-talk 
between ifnar1-EC and ifnar2-EC being tethered onto solid-supported, fluid lipid bilayers was 
investigated by RIfS and total internal reflection fluorescence spectroscopy. A very stable 
binding of IFNα2 at high receptor surface concentrations was observed. The apparent kd 
value was approximately 200-times lower than for ifnar2-EC alone. A strong dependency of 
this apparent kd on the receptor surface concentration suggested kinetic rather than static 
stabilization, which was corroborated by dynamic exchange experiments. Cellular binding 
assays as well as different ifnar1-EC fragments in vitro highlighted the key role of the 
membrane-proximal Ig-like domain for the formation of an in situ IFN-receptor complex and 
the ensuing signal activation. All these results suggested a two-step binding model: After 
ifnar2 recruitment by IFN, ifnar1 binding mediates ternary complex formation. The complex is 
stabilized by the transient interaction of ifnar1 with the ifnar2-bound ligand, which is several 
orders of magnitude more efficient for IFNβ than for IFNα2. Thus differential signaling is 
proposed to be encoded by the efficiency of signaling complex formation depending on the 
affinity of ifnar1-EC toward IFNs as well as on the receptor surface concentration. 
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3 Introduction 
3.1  Cytokines and cytokine receptors 
3.1.1 Overview  of  cytokines and cytokine receptors 
Cytokines are soluble proteins and glycoproteins mediating intercellular 
communication in a variety of physiological processes. Based on the structure three classes 
of cytokines are distinguished. Class I cytokines have a 4 short α-helix motif (each helix ~15 
residues), whereas cytokines of class II share a structural core of 4 long α-helices (each helix 
~25 residues). In contrast to class I and II, members of class III (TNFα/β) show no helical 
structure motifs but a set of β-sheets. It depends on the literature source if class III cytokines 
belong to the cytokines in the classical manner. 
Cytokines play a key role in regulating the immune system as a central element of 
innate immunity. A special characteristic of cytokines is the pleiotrophic effect, which means 
one cytokine is able to activate different activities in different cells. Different cytokines are 
also able to cause the same effect leading to accumulated cellular responses, which is 
termed cytokine redundancy. Cytokines are known to be involved in proliferation, 
differentiation, cell activation, embryogenesis, tissue repair and apoptosis. A short overview 
of cytokines and their functions is shown in Table 1.  
Cytokine receptors are classified by the structural arrangement of their extracellular 
domains. Characteristic sequences of domains, such as cysteine-rich domains, fibronectin 
type III-like domains and immunoglobulin-like domains vary in different receptor types. 
Another variable classification parameter is the subunit structure of different cytokine 
receptors. Some receptors form homodimers, other receptors have two or more subunits 
leading to a hetero-oligomeric structure. All subunits are proteins with one single 
transmembrane domain, an extracellular located N-terminal domain and an intracellular C-
terminal domain.  
Type I cytokine receptors (hematopoietin receptor family) consist of one or two 
polypeptide chains responsible for cytokine binding and an additional chain for signal 
transduction. The erythropoietin receptor, the growth hormone receptor and the G-CSF 
receptor belong to this receptor family. The IFNα/β receptor and IFNγ receptor represent the 
family of type II cytokine receptors (Interferon receptor family). Depending on the literature 
source the TNF receptor family belongs to the type III cytokine receptors with huge structural 
differences compared to the first two classes. 
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Table 1   Overview of cytokine function 
Cytokine  Producing cells  Target Cell  Function     Cytokine  Producing cells  Target Cell  Function 
               
Class I Cytokines          Class I Cytokines 
GM-CSF  Th cells  progenitor cells  growth and differentiation of     IFNγ  Th1 cells,   various  viral replication inhibition 
         monocytes and dentritic cells      Tc cells, NK cells  macrophages  MHC expression 
IL-1                
      
monocytes Th  cells co-stimulation pathogen  elimination
  macrophages   B cells  maturation and proliferation        activated B cells  Ig class switch to IgG2a 
  B cells   NK cells  activation           Th2 cells  proliferation 
   DC  various  inflammation, acute phase response, fever   
  activated T and B 
cells, 
 
Class II Cytokines    
   
   
IL-2 Th1  cells
NK cells 
growth, proliferation, activation 
  EPO kidney  cells    differentiation and proliferation  
IL-3  Th cells  stem cells  growth and differentiation             of erythrocytes 
   NK cells  mast cells  growth and histamine release    G-CSF  monocytes, 
macrophages, 
neutrophiles  
progenitor cells  proliferation and differentiation of  
hematopoietic progenitor cells 
IL-4  Th2 cells  activated B cells   proliferation and differentiation    IL-6  monocytes  activated B cells  differentiation into plasma cells 
      IgG1 and IgE synthesis      macrophages  plasma cells  antibody secretion 
    macrophages  MHC Class II expression      Th2 cells  stem cells  differentiation 
      T cells  proliferation       stromal cells  various  acute phase response 
          IL-10  Th2 cells  macrophages  cytokine production 
IL-5  Th2 cells  activated B cells  proliferation and differentiation          B cells  activation 
          
           
      
              
IgA  synthesis   IL-28/29 various various  Antiviral, but not antiproliferative  
effects 
marrow stroma,    (IFNλ)  IL-7 
thymus stroma 
stem cells  differentiation into progenitor B and T cells 
   IFNα 
 
leukocytes 
 
various 
 
viral replication inhibition 
IL-8  macrophages  neutrophils  chemotaxis          MHC I expression 
endothelial  cells   IFNβ  fibroblasts various viral replication inhibition 
IL-12  macrophages  activated Tc cells  differentiation into CTL              MHC I expression 
   B cells  NK cells   activation    
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One of the key questions of cytokine receptor signaling is: How is the signal 
propagated over the membrane? Since no structure of a complete cytokine receptor 
including transmembrane- and cytosolic domains has been published yet, the structural and 
dynamical determinants of signal activation are not understood. However, interactions of the 
extracellular domains of several receptors provided some evidences, that signal activation is 
propagated by ligand induced cross-linking of the receptor subunits. Thus, ligand recognition 
plays a key role in receptor cross-linking and has been studied for several receptors.    
3.1.2  Extracellular structure of type I cytokine receptors 
A hallmark for understanding cytokine-receptor structure and mechanism was the 
determination of the crystal structure of the growth hormone receptor complex [1-3]. This 
receptor consists of two identical subunits, each subunits contains two seven-stranded 
fibronectin III-like domains. Interestingly two ligand binding sites were identified on each 
subunit, mainly localized on the N-terminal fibronectin III-like domain. These two different 
binding sites mediate the cross linking of two single receptor molecules induced by one 
ligand (Figure 1A). Another interesting observation was the difference in affinity of the two 
binding sites, indicating a two-step binding mechanism. In the first step GH binds to the high 
affinity binding site of one subunit, in the second step, which takes place in plane of the 
membrane, the signaling complex is formed. That model is also supported by the contact 
area formed by the two C-terminal fibronectin III-like domains (Figure 1A). Thus ligand 
induced receptor cross-linking of the receptor subunits is proposed to initiate intracellular 
signaling.  
Another cytokine receptor forming a receptor homodimer together with one ligand 
molecule is the erythropoietin receptor (EPOR) [4]. As for GHR, ligand binding sites of the 
EPOR are mainly located on the N-terminal fibronectin III domain and the linker region 
(Figure 1B). In contrast to the GHR, for EPOR no receptor-receptor contacts were observed 
in the crystal structure, indicating different ways of receptor orientation for signal activation.  
AB AB
 
Figure 1  A, B: Crystal structure of the GHR (A) and the EPOR (B) complexes.  
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In contrast to GHR and EPOR, IL-4 recruits a heterodimeric receptor complex 
involving IL-4, IL-4R and a subunit called gamma chain (γC). The structure of IL-4/IL-4R was 
solved by crystallization [5] and in the binary complex two independent binding sites on IL-4R 
have been identified via mutagenesis [6]. These data indicate a stoichiometry of 1:1:1, but 
currently no ternary complex structure including γC has been determined. 
A 2:2 stoichiometry was found for the G-CSF:G-CSFR complex. In the 2:2 complex 
neither interactions between the G-CSF molecules nor interactions between the two receptor 
molecules could be observed. This complex was reported to be formed by two binary 
complexes of G-CSF:G-CSFR, again via a second ligand binding site. The first binding site, 
which is responsible for the formation of the 1:1 complex, is localized at the C-terminal 
domain in proximity to the linker region (Figure 2). This contradicts to the observations on 
other cytokine receptors, where the high affinity binding site is mainly localized at the N-
terminal domain. In this case, the region on G-CSF, which corresponds to the high affinity 
binding site on GH, mediates the formation of the 2:2 complex. In other studies higher 
stoichiometries up to 4:4 are proposed for this complex [7]. However the exact stoichiometry 
of the signaling complex remains to be elucidated.  
D1 D1
D2
D1
D1
D2
D2 AB
D2
 
Figure 2  A, B: Structure of the G-CSFR:G-CSF 2:2 complex, side view (A) and upview (B). The 
receptors are drawn in blue, the ligands in red. 
  
Also receptor-ligand complexes with a higher stoichiometry were investigated, for 
example the IL-6 receptor. This complex is arranged in a 2:2:2 stoichiometry of IL-6:IL-6R 
and gp130. The crystal structure of IL-6:gp130 was determined by using a viral homolog to 
human IL-6 (vIL-6), which has a comparable structure and function. In contrast to human 
IL-6, vIL-6 is able to activate signaling without forming a binary complex with IL-6R. The 
vIL-6:gp130 complex shows a two-fold symmetric ring structure with a bridge between the 
receptors formed by the ligands [8] (Figure 3). This arrangement is mediated by two different 
ligand binding sites on gp130. One binding site is localized on the N-terminal domain D1, the 
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other binding site which recruits the opposite vIL-6 is localized at domain D3. With human 
IL-6 a hexameric complex of IL-6:IL-6R/gp130 in a 2:2:2 stoichiometry was observed in 
single particle analysis [9] including the three C-terminal domains of gp130 (D4, D5 and D6). 
AB
 
Figure 3    Structure of the vIL-6-gp130 complex in 2:2 stoichiometry (as published in [8]). A: 
Ribbon scheme of the side view showing that each gp130 interacts with both vIL-6 
molecules via different domains. B: Top view demonstrating the ring structure of the 
complex. 
 
3.1.3  Type II cytokine receptors 
In contrast to some type I cytokine receptors, all type II cytokine receptors are 
heterodimers or multimers with a high and a low affinity component. Currently no complete 
complex structure of the extracellular domains of a type II cytokine receptor is available.  
For the IFNγR complex a stoichiometry of 2:2:2 was proposed, the solved structure 
shows a 2:2 complex of IFNγ and IFNγR1 [10] (Figure 4). In contrast to type I cytokine 
receptors, where dimerization is mediated via two different interaction sites on the ligand, 
dimerization of the IFNγR complex is driven by a ligand dimer. IFNγ forms a dimer in solution, 
which binds two IFNγR1 with high affinity (KD ~ 0.1 nM) at the identical binding site [10] 
(Figure 4). The membrane proximal domains of IFNγR1 receptors do not show a contact 
interface like GHR. The 2:2 complex binds two β-receptor chains (IFNγR2) that are specific to 
the type of responding cell [11]. The low affinity of IFNγR2 indicates a two-step binding 
mechanism.  
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Figure 4    Structure of IFNγ and IFNγRα in a 2:2 complex formation. This complex is recruited 
by two IFNγR chains to the signaling complex. 
 
Like IFNγ, IL-10 has 6 α-helices and forms also a dimer [12]. As shown for IFNγ the 
structure of the 2:2:2 complex has not been determined yet, but the structure of a 
IL-10:IL-10R1 complex has been solved by X-ray crystallography (reviewed in [13]). Based 
on this structure a model showing the 2:2:2 stoichiometry of IL-10:IL10R1:IL-10R2 was 
proposed (Figure 5). In this model two IL-10 dimers form a central ligand core. IL-10R1 and 
IL-10R2 are arranged in an anti-parallel manner on two sites. This prediction is based on 
crystallography results and measurements in solution, where two IL-10 dimers and four 
IL-10R1 molecules form a complex, which is not believed to be formed on the membrane.  
D1
D1
D1
D2
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Figure 5  Model of an IL-10/IL-10R1/IL-10R2 complex (kindly provided by Mark R. Walter). 
The localization of each Ig-like domain is labeled with D1 or D2 (green: IL-10R1, 
blue: IL-10R2). The model is based on the structure of IL-10/IL-10R1 determined by 
X-ray.  
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3.1.4  Mechanisms of cytokine receptor signaling 
As an initial step in cytokine signaling the ligand-induced assembly of the extracellular 
domains is suggested. This assembly is proposed to bring the intracellular domains into a 
closed proximity, which leads to cross- or autophosphorylation of receptor-associated 
kinases like JAK (Janus kinase). These activated kinases phosphorylate several tyrosine 
residues of the receptor cytoplasmic domains. In the next step STAT proteins (signal 
transducer and activator of transcription) dock to receptor subunits and become also 
phosphorylated by the associated kinases. The activated STATs are able to form homo- as 
well as heterodimers translocating to the nucleus. There they act as transcription factors and 
control the expression of response genes. 
Currently it is still under debate, how kinase activation is mediated by cytokine 
binding. One model is the ligand-induced cross-linking which is responsible for bringing the 
cytoplasmic domains into proximity leading to signal propagation. Based on different binding 
affinities of the subunits a two-step assembling was proposed. In this model it is possible to 
control responsiveness by varying the surface receptor concentration. For some cytokine 
receptors pre-assembly of receptors in an inactive state is proposed. Thus ligand binding 
leads to a conformational change of the pre-assembled subunits and not to a ligand-induced 
assembly.  
3.1.5  Type I cytokine receptor signaling 
The formation of a GH:GHR2 complex at the cell surface leads to an activation (by 
trans-phosphorylation) of the tyrosine kinase JAK2, which associates with the cytoplasmic 
domain after ligand binding (reviewed in [14]). The activated JAK2 phosphorylates GHR and 
STAT proteins activating a variety of cellular responses. Each domain has a high and a low 
affinity ligand binding site suggesting a sequential assembly. In the first step the high affinity 
binding site of GH binds to one GH receptor subunit. The second step, which takes place in 
plane of the membrane, is mediated by low affinity interactions [15, 16]. The interaction 
interface between two receptor domains was investigated in detail by mutagenesis [15, 17-
20]. On sub-domain 2 several residues were mutated leading to reduced signaling activity. 
Interestingly dimerization was not affected in these mutants. These results indicated that not 
only dimerization is required for signaling, but subtle structural changes can influence 
signaling activity. Still many other aspects like interactions between the transmembrane 
domains or the formation of intermolecular disulfide bonds have not been investigated yet.  
Another receptor system, which is studied in detail, is the erythropoietin receptor. Like 
GH also EPO is proposed to dimerize two receptor molecules sequentially in the membrane 
with one high affinity (KD ~ 1 nM) and one low affinity (KD ~ 1 µM) interaction [21] forming a 
EPO:EPOR2 complex. Studies with cross-linked EPOR dimers either covalently by 
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introduction of additional cysteines [22] or non-covalently by EPO-mimetic peptides [23] 
demonstrate, that a close proximity of receptors is necessary for activation. Either life-time or 
orientation of the receptor complex have strong influences on activity, demonstrated by 
different EPO-mimetic peptides [24, 25]. In contrast to the two-step assembly mechanism the 
existence of pre-associated, inactive EPOR dimers was proposed [26]. In this self-associated 
dimer the intracellular domains are suggested to be kept apart preventing background 
phosphorylation by associated JAK2 [27]. If EPO binds, structural changes of the 
extracellular domains promote a closer and correct proximity of the intracellular domains, 
which permits self-phosphorylation of JAK2 and thus initiates signaling (Figure 6, [4]). The 
model of a pre-assembled receptor based on crystallization data [26] was supported by an in 
vivo complementation assay [28]. Interestingly, also the transmembrane domains were also 
proposed to play a role in receptor pre-assembly [29]. However, a pre-assembly in an “off-
state” may promote a tight regulation of EPOR signaling. Similar pre-association of 
homodimeric complexes has been proposed for IL-1R [30] and IL-2R [31]. 
P
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Figure 6    Schematic of the EPO receptor complex [4]. A: Inactive “off-state” of the dimer with 
distantly arranged cytosolic domains. B: Liganded active receptor configuration. The 
cytosolic domains are in closed proximity and right orientation to each other, which 
enables JAK-2 mediated phosphorylation and signal cascade initiation.  
 
In contrast to EPOR and GHR several receptors forming heterodimers are described, 
e.g. the IL-4R. In the first step IL-4 binds specifically to IL-4αR, then to a so called γ-chain. 
This second protein is also involved in IL-2, IL-7 and IL-9 signaling [32], indicating broader 
intersections of different signaling pathways. Structurally the high affinity binding site of IL-
4αR corresponds to the low affinity site on GH or EPO [5].  
The protein gp130 is a shared signal-transducing receptor, involved in the signaling of 
IL-6, IL-11 and several other cytokines [33]. In the first step of IL-6 signaling, IL-6 binds 
specifically to the receptor IL-6R forming a binary complex. This complex is recognized by 
gp130 for the assembly of a trimolecular complex, which is not competent for signaling. Two 
ligand/receptor complexes then form a 2:2:2 complex in a manner that the N-terminus of 
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gp130 binds the opposite IL-6 (Figure 7, [8]). Interestingly, the intracellular domains of IL-6R 
seem not to be required for signal activation. This was demonstrated by experiments with a 
soluble complex of the extracellular domain of IL-6R and IL-6, which also leads to gp130 
mediated signal activation. Here, the formation of a binary complex of IL-6/IL-6R is required 
for gp130 binding, indicating a cooperative interaction of IL-6 and IL-6R with gp130. Thus, 
soluble splicing variants of gp130 (sgp130) and IL-6R (sIL-6R) are proposed to play a role in 
regulating IL-6 signaling. Soluble IL-6R was shown to increase IL-6 activity, whereas sgp130 
acts as a natural inhibitor of IL-6 signaling [34]. Interestingly the three membrane proximal 
domains of gp130 are proposed to keep the complex in a certain distance to the membrane 
[9]. This arrangement was suggested to enable a closed proximity of the C-terminal domains 
(D6) mediating signal activation. 
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Figure 7    Cartoon of IL-6 signaling. In the first step one ternary complex of IL-6/IL-6R and 
gp130 is formed. Subsequently two ternary complexes dimerize to a 2:2:2 complex, 
which activates intracellular signal transduction. 
  
3.1.6  Type II cytokine receptor signaling 
IFNγR consisting of IFNγR1 and IFNγR2 was proposed to be pre-assembled in an 
inactive state. In fluorescence transfer experiments it was obseved that ligand binding led to 
a decrease in FRET efficiency [35]. It was concluded, that this decay is due to a 
conformational change of a pre-assembled receptor (Figure 8). Probably an increase in 
receptor flexibility induced by ligand binding activates the receptor. Since IFNγ is a dimer, it 
binds two IFNγR1 but does not directly bind to IFNγR2 in the absence of IFNγR1. In contrast 
to a pre-formation, the observation of a high and a low affinity component also suggested a 
two-step binding mechanism with IFNγR1 as a binding protein and IFNγR2 as the activator of 
signal transduction.  
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Figure 8    Cartoon of IFNγR signal activation. Ligand induced conformational changes in the 
pre-associated complex generate kinase activity. 
 
3.2  Type I interferons 
Interferons mediate the antiviral activity as a first defense line and furthermore 
prevent secondary viral infections [36]. Three types of human interferons are classified by 
their receptors: type I, type II and type III. 13 non allelic IFNα sub-types, IFNβ, IFNε, IFNκ 
and IFNω   belong to the type I interferons. IFNγ is the only known type II interferon. 
Additionally four IFN-like cytokines, defined as type III interferons, have been reported 
recently: IFNλ1 (IL-29), IFNλ2 (IL-28A) and IFNλ3 (IL-28B) are found in humans and other 
mammals (reviewed in [37]). Here, only type I IFNs will be discussed in more detail. 
Exposure of cells to viruses or double stranded RNA (dsRNA) induces the production 
of IFNαs, IFNβ and IFNω. The level of each expressed IFN depends on the tissue of origin 
and the nature of viral challenge. Signaling induced by type I interferons plays a key role in 
host innate immunity by eliciting a pleiotrophic response including antiviral, antiproliferative, 
immunmodulatory and anti-inflammatory activities. These activities make type I IFNs to 
attractive candidates for a variety of clinical applications [38].  
IFNs affect certain levels of viral infection like transcription, translation, RNA stability, 
virus maturation and replication. The spectrum of cellular effects depends on IFN-stimulated 
cell type or tissue. Hundreds of genes were identified by DNA arrays to respond to IFN 
stimulation [39], but the whole network of IFN mediated signaling pathways has not been 
understood yet. Several signaling pathways propagating antiviral response were investigated 
in detail [40, 41]. The best characterized IFN-induced protein is the dsRNA dependent 
protein kinase R (PKR) [42]. It was predicted, that PKR specifically binds viral dsRNA and 
turns after autophosphorylation into the activated state by the exposition of the catalytic C-
terminal domain [43]. No sequence specificity has been identified yet. However, cellular 
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dsRNA (tRNA, rRNA) does not affect PKR activity. Once PKR is activated, it phosphorylates 
the eukaryotic initiation factor eIF-2 α-subunit resulting in the inhibition of translation 
initiation. This effect decreases host as well as virus protein synthesis and supports the 
propagation of an antiviral state. PKR is also known to phosphorylate histones inhibiting DNA 
synthesis, which drives antiproliferation. Other IFN-induced key enzymes are 2´,5´-
oligoadenylate-synthases (2-5A-sythases) producing short polymers of 2´,5´-oligoadenylate. 
This polymer activates RNAse F leading to extensive ssRNA digestion [44]. 2-5A binds 
inactive monomeric RNAse L and induces reversible formation of an active dimer [45]. 
Additionally 2-5A-sythases modify the Cap-structure of mRNA inhibiting the binding to the 
ribosome. Thus also translation level is affected by this enzyme.  
PKR and 2-5A-synthase act effectively during the antiviral response. Additionally 
several secondary effects supporting the efficiency of this primary response are known. Mx 
proteins belong to the GTPases in the dynamin superfamily and are also induced by IFNs. 
They interfere with viral growth and replication at the transcriptional and translational level 
[46, 47]. Fas is an apoptosis-propagating receptor protein inducing cell death after binding 
Fas ligand.  
Also elements of the adaptive immune system are known to be stimulated by IFNs. 
The increased level of antigen-MHC-I at the cell surface activates cytotoxic T-lymphocytes 
(CD8
+) eliminating infected cells, so viruses lose their replication hosts. Also the expressions 
of TAP, proteasome components and chemokines are influenced by IFNs. Proteasomes and 
TAP propagate the antigen pathway by cleavage of virus proteins to peptides and their 
loading to MHC-I via the TAP complex. Thus IFNs are elements of innate immunity, which 
furthermore initiate responses by the adaptive immune system. 
Interferons have been used in clinical applications for two decades for different 
diseases. Recombinant IFNα2 was the first IFN used as a drug for treatment of hairy cell 
leukemia and Kaposi´s sarcoma [48]. Today different preparations of IFNα2 (Pegasys
®, 
Roferon
®, IntronA
®) and IFNβ (Rebif
®, Avonex
®, Betaferon
®) are used in a variety of cancers 
and viral diseases. For example chromic myelogenous leukemia and metastatic malignant 
myeloma have been successfully treated with IFNα2 [49, 50]. Because of its antiviral activity 
IFNα2 has also been approved for the therapy of chronic hepatitis B [51] and C [52], liver 
diseases caused by HCV infection. The potent antiviral and immunmodulatory activity proved 
in cell culture propagate IFNα2 as a drug candidate for many other viral infections, e.g. HIV. 
However, only minor effects in the treatment of retroviral diseases were observed [53]. The 
anti-inflammatory character of IFNβ is used for the treatment of relapsing-remitting multiple 
sclerosis [54]. It is not able to eliminate the disease, but it is proposed that by migration 
inhibition of activated T-lymphocytes into the nervous system the velocity of neuron 
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degradation is reduced [55]. As for many other biotherapeutics, side effects often cause 
interruption or dosage limitation in IFN therapy. Also antibodies generated during the therapy 
can reduce the efficiency of IFN treatment dramatically [56]. Currently several modifications 
of IFNα2 (e.g. different PEGylations) are used in clinical trials for a variety of further 
applications, mainly cancer diseases [57].  
3.3  The human type I interferon receptor ifnar 
3.3.1 Overview 
All human type I interferons exert activity through binding to the same receptor 
subunits, ifnar1 [58] and ifnar2 [59]. Ifnar1 and ifnar2 are transmembrane proteins with an 
extracellular domain (EC), a trans-membrane domain (TMD) and an intracellular domain 
(CP) associated with JAK1 (ifnar2) or Tyk2 (ifnar1) (Figure 9). Based on sequence alignment 
of the extracellular domains both receptor components belong to the type II cytokine receptor 
family [60]. Typically the extracellular domains of this receptor family are divided into two Ig-
like domains (7 β-sheets with one disulfide bond) consisting of ~100 residues each and 
forming one cytokine binding module (CBM) [61]. Ifnar2-EC forms one CBM and the 
structure was solved by NMR [62]. Interestingly ifnar1-EC consists of ~400 residues, twice of 
the size of ifnar2-EC. This suggests two CBMs and a more complex stoichiometry than the 
1:1:1 complex of ifnar1-EC, ifnar2-EC and IFNβ observed in solution [63]. In contrast to 
ifnar2-EC no structural data from NMR or crystallography are currently available for ifnar1-
EC. 
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Figure 9    Schematic of the human type I interferon complex and associated signaling pathways. 
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3.3.2  Signal transduction induced by IFN mediated receptor assembly 
For the type I IFN receptor a signaling complex formation by the ligand-induced 
assembly of the two receptor subunits ifnar1 and ifnar2 is suggested (Figure 9). In this 
signaling complex the tyrosine kinases JAK1 and Tyk2 associated with the cytoplasmic 
domains are activated by auto-phosphorylation, followed by phosphorylation of several 
tyrosine residues on the receptor and other effector molecules, which are mainly members of 
the STAT family. STAT1 and STAT2 play a central role in type I IFN signaling. After 
phosphorylation together with p48 a STAT1/STAT2 heterodimer forms the transcription factor 
ISGF3. This factor activates the transcription of interferon-stimulated genes (ISGs) genes in 
the cell nucleus by binding to interferon-stimulated regulatory elements (ISREs) [40, 41, 64]. 
But also other members of the STAT family (STAT3 and STAT5) were identified to form 
homo- or heterodimers after IFN stimulation leading to the activation of different signaling 
pathways. 
Another pathway induced by IFN receptor assembly is the IRS/PI-3-K pathway [65]. 
The IRS (insulin  receptor  substrate) family consists of 6 proteins with several 
phosphorylation sites, which act as binding sites for SH2-domains. During receptor activation 
IRS-1 binds to the ifnar cytoplamic domain and is subsequently phosphorylated on different 
tyrosines. After dissociation from the receptor IRS-1 activates the PI-3-K (phosphatidyl-
inositol-3-kinase) enzyme subunit p85 via SH2 interaction. The second subunit p110, were 
phophoinositol- and serinkinase activity are located, subsequently binds to p85 and the 
activated enzyme leads to a variety of signaling processes [41]. In addition, downstream 
effectors like the Ser/Thr kinase Akt activates the nuclear factor κB [66], which is involved in 
apoptosis and cell cycle arrest. Also P21(ras)/Raf-1/MAPK are activated by type I IFNs [37]. 
Also the tumor-suppressor p53 is reported to be induced by interferons [67]. These pathways 
are proposed to be responsible for the antiproliferative and pro-apoptotic character of type I 
interferons.  
It appears that the function of the 15 known human type I interferons is not fully 
redundant, but that differential signaling by different IFNs can be observed [68-73]. In 
particular between IFNα subtypes and IFNβ, substantial differences have been observed on 
the level of receptor phosphorylation [68] and effector recruitment [74], as well as on the level 
of gene induction [75]. As no further receptor component has yet been identified, these 
differences have to be explained through the mode of interaction of IFNs with the 
extracellular domains of ifnar1 and ifnar2. Therefore, a comprehensive structural, biophysical 
and mechanistic picture of how the receptor domains are recruited in time and space is 
required for understanding the specificity of signal propagation though the membrane. The 
differences in affinity, binding kinetics, recognition and bindings modes, which have been so 
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far reported for the interaction of IFNα2 and IFNβ with ifnar2-EC are only minute [76, 77] and 
therefore can hardly explain the functional differences. The interaction between ifnar1 and 
IFN has been reported to be of much lower affinity and its contribution towards complex 
formation is less well characterized, because the properties of cell surface receptor such as 
affinity and competitiveness is dictated by the (high-affinity) interaction with ifnar2.  
3.3.3 Structure-function  relationships 
The 3-dimensional structures of IFNα2 [78] and IFNβ [79] were determined by 
crystallography. Both interferons consist of 5 α-helices (A-E) which are connected via loops 
and short 310-helices (Figure 10). Helices A and B are ordered to each other in a parallel 
manner, to helices C, D and E they are oriented anti-parallel. While helix D is part of a loop 
connecting helices C and E, helices A, B, C and E form a 4 helix bundle (Figure 10A), a very 
compact and stable structure mediating type I IFNs´ temperature and pH resistance. Both 
IFNs obtain a disulfide-bond linking AB- and DE loop (IFNα2: C29-C139; IFNβ: C31-C141). 
IFNβ, which is glycosylated (N80), has an additional free cysteine (C17). IFNα2 subtypes 
have an additional disulfide-bond between C1 and C98, which is not essential for receptor 
binding.  
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Figure 10  A: Structure of IFNα2 determined by NMR. Helices A, B, C and E are arranged in a 
4-helix bundle. B: Structure of IFNβ with glycosylation solved by X-ray analysis. 
The interaction between IFNα2 and the high affinity receptor component ifnar2 was 
well characterized by mutagenesis  [76, 80]. The structure of the binary complex based on 
double mutant cycle analysis is shown in Figure 11. On IFNα2 a core binding site to ifnar2 is 
formed by 6 residues (L30, R33, R144, A145, M148 and R149). R144, A145, M148 and 
R149 are localized in the E-helix. L30, A145 and M148 form together with L26 and F27 a 
hydrophobic pocket. Ten additional amino acids on helices A and E are involved in ifnar2 
binding mainly by electrostatic interactions. For binding IFNα2 and IFNβ the same residues 
on ifnar2 are involved, but these residues are differently accentuated [76]. For IFNα2 binding 
T46, I47 and M48 were determined to form a “hot spot”, for binding of IFNβ another set of 
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residues (I47, H78, N100, W102) accentuates the interaction. The 3-D structure of ifnar2-EC 
was successfully solved by NMR studies [62] and modeled to IFNa2 based on double mutant 
cycle analysis data (Figure 12).  
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Figure 11    Model of ifnar2-EC with residues involved in binding of IFNα2 (A) and IFNβ (B). 
Color coding corresponds to the decrease in binding affinity (red: >10-fold, orange: 
>3-fold, yellow: <3-fold, blue: <50%, green: increase). 
   
Figure 12    Structure of the ifnar2-EC-IFNα2 obtained by double mutant cycle analysis (same 
color coding as in Figure 10). The structure of ifnar2-EC was determined by NMR 
analysis. 
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In contrast to ifnar2 much less is known about the interaction between type I IFNs and 
the low affinity component ifnar1 (with a KD in the µM range). One method to investigate 
ifnar1 was monitoring its effect on the high affinity ifnar2-IFN interaction upon ternary 
complex formation, i.e. the activity of ifnar1 was indirectly detected. In such experiments 
different binding sites for IFNα and IFNβ on human ifnar1 were predicted by using 
neutralizing anti-ifnar1-antibodies [81]. Antibody binding of different epitopes inhibited 
specifically the transcription of IFNα or IFNβ target genes [82]. However, it was not shown 
that the epitopes for the antibodies correlate with the IFN binding sites. To identify those 
epitopes, direct interaction between ifnar1 and IFN was investigated. Because of the low 
affinity of ifnar1, bovine ifnar1, which has a much higher affinity for human IFNα2 (KD ~ 
10 nM), was used. Thus, specific binding of IFNα2 to cells transfected with bovine ifnar1 
could be detected. By using human/bovine chimeras of ifnar1, SD2 and SD3 were identified 
to play an essential role in IFN binding [83]. SD1 and SD4 also appeared to be involved in 
ligand binding. These results were confirmed by site directed mutagenesis on bovine ifnar1 
[84]. In this study the most identified residues were located on SD2 and SD3 while SD1 and 
SD4 play a minor but significant role in IFN binding. In order to map the ligand binding site on 
human ifnar1, several mutants were investigated by cellular binding assays [85]. The peptide 
62FSLKLNVY
70 on SD1 and W129 were identified to be crucial for IFNα binding and biological 
activity. Interestingly 
278LRV on SD3 is not critical for binding but for biological activity. Based 
on this result a model was predicted, where SD1 and SD2 act as a lid of a closed signaling 
complex indicating the closing mechanism as the trigger for differential signaling.  
The general limitation of these strategies, the direct detection with bovine ifnar1 as 
well as the indirect detection via ifnar2, is the dependency on cellular systems. In these 
experiments receptor surface expression has to be strictly controlled, because the binding 
efficiency is expected to depend strongly on the receptor surface concentration (absolute 
surface concentration) and on the ratio between ifnar1 and ifnar2 (relative concentration). 
Furthermore, stoichiometry or individual contributions of single ifnar1 sub-domains are very 
difficult to be quantitatively investigated on cells.  
However, an effective expression and purification system for studying the interaction 
in vitro has not been established yet. Functional ifnar1-EC was successfully expressed in P. 
pastoris, but very low yields were obtained (personal communication with R. Arduini). A 1:1:1 
complex of ifnar1-EC, ifnar2-EC and IFNβ (but not with IFNα2) was detected by size 
exclusion chromatography [63]. As no direct interaction between IFNβ and ifnar1-EC was 
shown under these conditions, this result indicated that cooperative interaction leads to 
stabilization of the ternary complex as shown for IL-6/IL6-R and gp130. These initial results 
could not explain differences between individual IFNs with respect to the role of signaling 
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complex stoichiometry, the dynamics or binding sites. To address these questions as well as 
to confirm cooperative effects an effective in vitro assay has to be established.  
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Figure  13  Model of ifnar1-EC based on the structure of ifnar2-EC (SD: sub-domain, red: 
α-helix, blue: β-sheet) 
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3.4 Objectives 
All IFNs recruit only one receptor with the subunits ifnar1 and ifnar2. Thus differential 
signaling has to be encoded in the ligand recognition process of the extracellular domains of 
ifnar1 and ifnar2. Since ifnar1 appears to be responsible for mediating differential signaling, 
the goal of this work was to define the role of ifnar1-EC in the formation of the signaling 
complex. In this context also possible differences between individual IFNs had to be 
elucidated. In order to quantitatively investigate stoichiometry, thermodynamics, kinetics and 
the structural organisation of the ligand recognition process under controlled surface 
conditions, an effective in vitro approach was followed.  
Thus, an efficient expression and purification strategy for ifnar1-EC had to be 
developed. To achieve quantitative amounts of protein, expression was tried in different 
compartments of E. coli as well as Sf9 insect cells. For the analysis of individual interactions 
governing complex assembly, receptor subunits had to be tethered functionally in an oriented 
manner onto a glass surface. Then Immobilized receptors could be used to probe 
stoichiometry, thermodynamics and kinetics of different IFNs solid phase detection. In order 
to identify possible differences between IFNα2 and IFNβ in terms of  binding sites, different 
ifnar1-EC sub-fragments and mutants had to be generated. One major issue was the 
investigation of the whole signaling complex in an environment comparable to cell surface 
conditions. This objective was addressed by the co-immobilization of both receptor subunits 
on a solid-supported lipid bilayer mimicking the lateral mobility of the cell membrane. 
Immobilization had to be mediated by tethering the proteins via their his-tags onto a lipid 
which is covalently linked to a multivalent chelator head group. With this immobilization 
technique, in combination with surface-sensitive fluorescence detection, complex 
stoichiometry, dynamics and architecture were investigated. Thus this work should help to 
draw a detailed picture of complex assembly and should answer the question, how the 
determinants governing complex assembly are correlated with differential signaling. 
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3.5 Strategy 
3.5.1  Ifnar1-EC expression in quantitative amounts 
For the investigation of ligand-receptor interactions in vitro adequate amounts of all 
required proteins were necessary. The extracellular domain of ifnar2 and IFNα2 have been 
successfully expressed in E. coli, refolded and purified in amounts of 2-3 mg/l [86]. In 
contrast establishing an expression and purification strategy for ifnar1-EC was a challenge. 
The key problem of ifnar1-EC expression was the formation of 4 predicted disulfide bonds in 
the Ig-like domains [60]. Different expression systems in E. coli were tried to express 
properly folded ifnar1-EC. As described for ifnar2-EC [87] refolding from inclusion bodies 
(reviewed in [88]) was investigated, but without success. Ifnar1-EC was not monomeric and 
the cysteines were still reduced. Also fusing ifnar1-EC to the maltose binding protein (MBP) 
was tried. MBP was predicted to act as an intramolecular chaperone by mediating proper 
folding of the target protein and preventing aggregation [89]. MBP-Ifnar1-EC was expressed 
in the cytoplasm by using the expression vector pMAL-c2X, but only aggregated fusion 
protein was detected. In order to express ifnar1-EC in an oxidative environment the E. coli 
strain FA113 with an oxidizing cytoplasm was used for ifnar1-EC expression. This strain 
lacks reducing cytoplasmic enzymes and was used for successful expression of antibody 
Fab fragments [90]. For ifnar1-EC, however, no monodispers protein was detectable. As an 
alternative, periplasmic expression was tried using expression plasmids carrying a 
translocation sequence (pMAL-p2X and pASK-IBA2). For MBP-ifnar1-EC no secretion into 
the periplasm was detectable, but ifnar1-EC expressed with pASK-IBA2 could be 
successfully purified from periplasm via a C-terminal strep-tagII [91]. Size exclusion 
chromatography and a shift in SDS-PAGE towards a lower molecular weight after DTT-
treatment demonstrated, that ifnar1-EC was monomeric and carried disulfide bonds. Since 
yields were low (50 µg/l), E. coli were cultivated in a 10 l fermenter. In order to tether 
ifnar1-EC to chelator surfaces, the strep-tagII was exchanged by a deca-histidine-tag. This 
exchange led to protein aggregation probably during IMAC. Based on all results with 
expression in E. coli, it was decided to stop expression with this organism. The expression of 
ifnar1-EC in P. pastoris was also proposed to deliver low yields by applying a complicated 
purification and deglycosylation procedure [63].  
Spodoptera frugiperda 9 (Sf9) in combination with the baculovirus AcNPV [92] was 
chosen as an alternative new expression host to address the problems of low yields, folding 
and stability. Compared to E. coli or P. pastoris, insect cells are phylogenetically closer to 
human cells promising a higher probability of successful expression of human proteins 
compared to bacteria or yeast. The disulfide bond formation and especially the glycosylation 
during the secretory pathway were expected to increase solubility as well as stability of 
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heterologously expressed proteins. This was successfully demonstrated for the expression of 
gp130, IL-6R  [9] and several other cytokine receptors in Sf9.  
Baculoviruses (family Baculoviridae) belong to a group of large, double-stranded DNA 
viruses that infect specifically different insect species as their natural hosts. They were not 
known to propagate in any non-invertebrate host, which makes handling very simple. During 
an infection cycle a variety of viral proteins responsible for replication and budding were 
expressed. By inserting a gene of choice into the baculoviral genome heterologous protein 
expression was possible.  
In baculoviruses several genes were replaced by heterologous genes, which were 
transcribed during the virus replication cycle. The genes of interest had to be inserted into 
the virus genome via homologous recombination. Two different procedures for homologous 
recombination were available using a cloning vector as a gene shuttle. In the Bac-to-Bac 
system (Invitrogen) the recombination and selection of positive clones takes place in E. coli, 
transfected with the viral genome. The product of the recombination, the “bacmid”, was then 
transfected to Sf9 cells starting viral infection. The alternative to this system is the 
recombination directly in the host cells with the advantage to prevent the time consuming 
selection in E. coli. In this study a linearized genomic viral DNA and the transfer vector were 
co-transfected into Sf9 cells allowing recircularization of the virus DNA by homologous 
recombination. Since only circularized virus DNA is able to be transcribed and replicated, 
homologous recombination acts simultaneously as a selection marker for successful gene 
insertion. In this process also the heterologous gene is inserted into the virus genome. Here, 
with respect to time and economic reasons, a baculovirus expression vector system 
(Baculogold®, BD Bioscience) based on the Autographa californica nuclear polyhedrosis 
virus (AcNPV) was used for generating baculoviruses carrying ifnar1-EC via homologous 
recombination in Sf9 cells. 
Ifnar1-EC was cloned into the transfer vector pAcGP67-B, which could be used for all 
cloning procedures in E. coli. It carried several features, which were expected to be 
necessary for successful ifnar1-EC expression. A polyhedrin promoter with a downstream 
localized multiple cloning site promoted high expression levels in the late phase of viral 
replication. The multiple cloning site enables a very flexible handling with respect to insertion 
of additional linkers. Recombination sequences flanking the cloning region facilitated 
homologous recombination with the linearized viral DNA. The N-terminal secretion sequence 
of the viral gp67 protein initiated the secretion pathway of ifnar1-EC, ensuring the formation 
of disulfide bonds, a specific glycosylation and finally the secretion into the medium. This 
secretion was also the first step in purification.  
 26   Introduction 
3.5.2  Ifnar1-EC sub-fragments and mutants 
The amino acid sequence of ifnar1-EC was derived from sequence alignments with 
other cytokine receptors [60]. Four Ig-like domains of ~100 amino acids were predicted to 
form two cytokine binding modules indicating two potential ligand binding sites. To elucidate 
the contribution of each cytokine binding module for ligand binding, ifnar-EC was genetically 
cut at the predicted linker region. With respect to Ig-like domains and position of the his-tag 
the products of this procedure were termed H10-SD12 and SD34-H10. In contradiction to the 
hypothesis of two CBMs, SD2 and SD3 were considered to form the ligand binding site for 
IFNα2 and IFNβ in a non-classical manner [84]. For the identification of the sub-domains 
involved in ligand binding H10-SD123 and SD234-H10 were cloned, also to probe 
differences in the binding sites for IFNα2 and IFNβ. The sequences of SD12, SD34, SD123 
and SD234 (Figure 14A) were based on the alignment of different cytokine receptors. Since 
the linker regions between the individual domains were not well determined, short overlaps 
were generated in designing the proteins to prevent affecting the structure integrity.  
For investigating the role of receptor orientation in forming the ternary complex, 
H10-tags were fused to the C- or N-termini of ifnar1-EC as well as SD123. Also a constructs 
of ifnar1-EC with N- and C-terminal tag (SD1234-DT) was expressed to mimic a proposed 
two-fold attachment to the surface. The immobilization mode of the different ifnar1-EC 
constructs is schematically shown in Figure 14B.  
For investigating the role of the membrane proximal SD4 several constructs were 
designed. SD4 was replaced by Ig-like domains of human IFNλ receptor (LRSD2) and IL-10 
receptor (IL10R2D2) (Figure 15). These constructs addressed the question, if SD4 acts as a 
spacer or if it has a specific role in complex formation. To verify this question IFN binding on 
cells (performed in the group of Gilles Uzé, CNRS Montpellier) and on surfaces was 
investigated. In addition the construct V1V2 deriving from IL-10-R2D2 was cloned. Two 
amino acid cassettes of ifnar1-EC were re-introduced to get a detailed picture of the 
arrangement of SD4 with special respect to the C-terminus (Figure 15). 
In the cloning strategy (Figure 16) initially SD1234-DT was cloned by an N-terminal 
linker-insertion of a deca-histdine tag (via BamHI) into the transfection vector pAcGP67-B. 
H10-SD1234, H10-SD12, SD34-H10, H10-SD123 and SD234-H10 were derived from this 
construct. For the preparation of SD123-H10 first the sequence without a tag was cloned 
followed by the insertion of an H10-tag via EcoRI, which enables further insertions of other 
tags or fusion proteins. All other constructs were cloned via classical cloning (PCR and 
ligation). Mutants with exchanged residues were generated by ligase chain reaction (LCR). 
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10 20 30 40 50 60
....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....|
KNLKSPQKVEVD I IDDNF I LRWNRSDESVGNVTFSFDYQKTGM DNWIKLSGCQN ITSTKC
70 80 90 100 110 120
....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....|
NFSSLKLNVYEE IKLR IRAEKENTSSWYEVDSFTPFRKAQIGPPEVHLEAEDKA IV IH IS
130 140 150 160 170 180
....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....|
PGTKDSVM WALDGLSFTYSLL IWKNSSGVEER I EN IYSRHK IYKLSPETTYCLKVKAALL
190 200 210 220 230 240
....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....|
TSWK IGVYSPVHC IKTTVENELPPPEN IEVSVQNQNYVLKWDYTYANMTFQVQWLHAFLK
250 260 270 280 290 300
....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....|
RNPGNHLYKWKQ I PDCENVKTTQCVFPQNVFQKG IYLLRVQASDGNNTSFWSEE IKFDTE
310 320 330 340 350 360
....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....|
IQ AFLLPP VFNIRSLSDSFHIYIG APKQ SG NTP V IQDYPLIYEI IF WENTSNAE RKI IEK
370 380 390 400
....| ....| ....| ....| ....| ....| ....| ....| ....| ....
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Figure 14  A: Sequence of ifnar1-EC and the different sub-fragments. The arrows indicate three 
proline-rich regions of the transition between two Ig-like domains. B: Schematic of 
ifnar1-EC constructs and their attachment to the surfaces via N- and C-terminal 
decahistidine-tags. 
 28   Introduction 
10 20 30 40 50 60
....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....| ....|
SD4 PPVFNIRSLSDSFHIYIGAPKQSGN----TPVIQDYPLIYEIIFWENTS-NAERKIIEKK
LRSD2 PPVL-VLTQTEEILSANATYQLP-----PCMPPLDLKYEVAFWKEGAGNKTLFPVTPHGQ
PPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYNSWTYNVQYW
VLTQTEEILSANATYQLP-----PCMPPLDLKYEVAFWKEGAGNKTLFPVTPHGQ
IL10R2D2 PPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYNSWTYNVQYWKNGT-DEKFQITPQY KNGT-DEKFQITPQY
V1V2 ifnar1-EC IL10R2D2 IL10R2D2
70 80 90 100
....| ....| ....| ....| ....| ....| ....| ....| ....| ...
TDVTVPNLKPLTVYCVKARAHTMDEKLNKSSVFSDAVCEKTKPGNTSK
PVQITLQPAA
70 80 90 100
....| ....| ....| ....| ....| ....| ....| ....| ....| ...
SD4 TDVTVPNLKPLTVYCVKARAHTMDEKLNKSSVFSDAVCEKTKPGNTSK
LRSD2 PVQITLQPAASEHHCLSARTIYTFS-VPKYSKFSKPTCFLLEVPEAN-
IL10R2D2 DFEVLRNLEPWTTYCVQVRGFLPDR--NKAGEWSEPVCEQTTHDETV-
V1V2 ifnar1-EC IL10R2D2  
Figure  15  Sequence alignment of sub-domain 4 with LRSD2, IL10R2D2 and IL10R2-V1V2. 
Black: identical residue, grey: homolog residue. 
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Figure 16  Cloning strategy of different ifnar1-EC sub-fragments. Details in the text. 
 
3.5.3 Detection  techniques 
Since low affinity for the interaction of ifnar1-EC with IFNα2 and IFNβ was expected, 
a detection method for monitoring transient interactions was necessary. Therefore label-free 
solid phase detection by reflectometric interference spectroscopy (RIfS) was applied. This 
technique is based on the change in optical thickness caused by mass deposition on a glass 
surface. RIfS detects selectively binding processes at the surface, whereas processes in the 
bulk are not monitored (Figure 17A). As a read out either the shift of the interference 
maximum or the interference change at a defined wavelength can be used to monitor protein 
binding at the surface (Figure 17B). Here, protein immobilization (Figure 17C) or lipid fusion 
shifted the interference pattern. Since the signal was proportional to immobilized mass, the 
amount of immobilized protein can be absolutely quantified. Thus the stoichiometry between 
interaction partners by taking their molecular masses into account can be determined. The 
affinities of IFN toward ifnar1-EC or ifnar2-EC are calculated from rate constants or 
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equilibrium signals. A particular advantage for the detection of low affinity interactions are 
much less critical background signals in RIfS-detection [93] compared to evanescent field 
detection. 
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Figure 17  Schematic of RIfS detection method. A: Protein immobilization causes a change in the 
optical thickness leading to a shift in interference pattern.   
 
Total internal reflection fluorescence spectroscopy (TIRFS) is a surface sensitive 
method to detect binding processes on surfaces. Here, a total internal reflected light beam 
generates an evanescent field at the surface, which excitates fluorescence only close to the 
surface (100-200 nm). Fluorescence detection provided means for more detailed mechanistic 
analysis. In order to discriminate interactions of different ligands with ifnar1-EC, TIRFS was 
applied to monitor competition between labeled IFNα2 and unlabeled IFNβ.  
For mechanistic understanding of ternary complex dynamics, exchange processes 
were investigated by chasing labeled with unlabeled IFNα2 at the complex. Another 
application of TIRFS, also for studying receptor complex dynamics, was probing interactions 
at very low receptor surface concentrations. Here the receptor surface concentration was 
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decreased but the ratio between ifnar1-EC and ifnar2-EC was still kept constant. Because of 
its high sensitivity binding processes at low receptor surface concentrations were monitored.  
For all experiments using TIRFS also the RIfS signal was simultaneously monitored 
as a control. Thus receptor surface concentrations and stoichiometries could be quantified 
[94] (Figure 18). 
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Figure 18  Schematic of the set-up for simultaneous TIRFS-RIf detection. A laser beam excitates 
the surface generating the TRIF signal. A filter wheel mediates the specific detection 
of fluorescence at a photomultiplier (PMT). In parallel light for Rif signal is generated 
by a halogen lamp, reflected at the surface, filtered and detected at 800 nm by the 
second photomultiplier.  
3.5.4 Immobilization  techniques 
For probing receptor-ligand interaction on surfaces, receptor proteins were tethered in 
a site-specific manner onto the signal-transducer by their C-terminal decahistidine-tag (H10-
tag). Since histidine coordinates transition metal ions, his-tagged proteins could be tethered 
to metal loaded chelator surfaces. In this case a new class of multivalent chelators [95] was 
used for ifnar1-EC and ifnar2-EC immobilization. 
Two modes of chelator surfaces were used in this work. First the chelator was 
covalently linked to a PEG-polymer brush (Figure 19A). The advantages of this method were 
the stability of the surface and a simple handling of the chip, which could be used for days. 
The chelator was fixed very tightly to the polymer brush, so immobilized proteins were 
predicted to have no lateral mobility (non-fluid support). This immobilization technique was 
applied for probing individual interactions, because no receptor cross-talk was expected. 
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To mediate receptor cross-talk between ifnar1-EC and ifnar2-EC, lateral fluidity was 
required. For this reason a multivalent chelator headgroup (bis-NTA) covalently linked to a 
lipid, a so called chelator lipid [95] (Figure 19C) was used. It was integrated into a solid 
supported lipid bilayer (Figure 19B). Thus, immobilized ifnar1-EC and ifnar2-EC were 
expected to be properly oriented to each other in a ligand induced signaling complex. In all 
experiments with co-immobilized ifnar1-EC and ifnar2-EC this fluid support was applied.  
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Figure  19  Probing interactions between IFN and immobilized receptor subunits on different 
supports. In the first step NTA is loaded with Ni
2+ (I), then the receptor is immobilized 
(II). Finally the IFN is injected (III). A: Individual interaction between ifnar1-EC and 
IFN on a covalently linked Ni
2+-NTA. B: Reconstitution of both extracellular domains 
on supported lipid bilayers mimicking lateral mobility in plane of the membrane. C: 
Structure of the bis-NTA chelator lipid. 
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4 Materials 
4.1 Chemicals 
Name Company 
4-Chloro-1-naphthol Sigma-Aldrich 
5-Bromo-4-chloro-3-indoylphosphate  Sigma Chemical CO. 
Acetic acid 99%  Riedel de Haen GmbH 
Acryl amide 30% (w/v)  Carl Roth GmbH 
Agar GibcoBRL 
Agarose  Sigma Chemical CO. 
ATP Roche  Diagnostics  GmbH 
Avidin Fluka  Chemie  GmbH 
Bovine Serum Albumin (BSA)  Sigma Chemical CO. 
Bromphenolblue Merck  KGaA 
Coomassie Brilliant Blue  Sigma Chemical CO. 
D-(+)-Saccharose Carl  Roth  GmbH 
Dimethylsulfoxide (DMSO)  Fluka Chemie GmbH 
EDTA, Disodiumsalt  Carl Roth GmbH 
Ethanol, abs.  Riedel de Haen GmbH 
Ethidiumbromide Merck  KGaA 
Glycerol Carl  Roth  GmbH 
Glycine Carl  Roth  GmbH 
HEPES  Sigma Chemical CO. 
Imidazole  Sigma Chemical CO. 
IPTG PeqLab 
Magnesiumchloride  Riedel de Haen GmbH 
Methanol  Riedel de Haen GmbH 
N,N-Dimethylformamid (DMF)  Fluka Chemie GmbH 
Nitrotetrazoliumblue (NBT)  Sigma Chemical CO. 
Polyethylenglycol  Sigma Chemical CO. 
Hydrochloric acid, 37 %  Merck KGaA 
Sodiumacetate Sigma-Aldrich 
Sodiumchloride  Riedel de Haen GmbH 
Sodiumdodecylsulfate (SDS)  Carl Roth GmbH 
Sodiumhydroxide  Riedel de Haen GmbH 
Tris Carl  Roth  GmbH 
Triton X-100  Carl Roth GmbH 
Tween 20  Sigma Chemical CO. 
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Urea Carl  Roth  GmbH 
Hydrogenperoxide 30%  Merck KGaA 
 
4.2  Cells, Media and Transfection material  
Name Company 
Ampicillin  Sigma Chemical CO. 
Baculogold linearized baculoviral DNA  BD Bioscience Pharmingen 
Fetal Calf Serum (FCS)  Biochrom AG 
Penicillin/Streptolysin 100x  PAA laboratories GmbH 
Peptone/tryptone from casein  Carl Roth GmbH 
Pluronic F68, 10%  Invitrogen 
SF900-II insect cell medium  Invitrogen 
Tranfection Buffer A & B  BD Bioscience Pharmingen 
Yeast extract  Carl Roth GmbH 
 
4.3  Enzymes, plasmids and reaction buffers 
Name Company 
1 kb DNA-Ladder  New Engand Biolabs 
100 bp DNA-Ladder  New Engand Biolabs 
Amp-Ligase  Perbio Scinece 
Calf Intestine Alkaline Phosphatase (CIAP) New Engand Biolabs 
dNTP-Mix peqlab  laboratories 
DpnI  New Engand Biolabs 
EcoRI MBI  Fermentas 
EndoH  New Engand Biolabs 
NEBuffer 1-4  New Engand Biolabs 
NP-40  New Engand Biolabs 
NTA-AP-Conjugate Qiagen  GmbH 
Nucleobond Plasmid Purification Kit (Midi)  Macherey & Nagel 
Nucleospin Plasmid Purification Kit (Mini)  Macherey & Nagel 
P7-Buffer (for PNGaseF)  New Engand Biolabs 
pAcGP67-B plasmid DNA  BD Bioscience Pharmingen 
PNGaseF  New Engand Biolabs 
 34   Materials 
PNK-Buffer A  MBI Fermentas 
Polynucleotide-kinase A (PNK A)  MBI Fermentas 
PstI  New Engand Biolabs 
Pwo-Buffer (+/- MgSO4)  peqlab laboratories 
Pwo-DNA-Polymerase  peqlab laboratories 
Qiaex II Gel Extraction Kit  Qiagen GmbH 
Qiaquick PCR Purification Kit  Qiagen GmbH 
T4-DNA-Ligase  MBI Fermentas 
T4-Polynucleotide-Kinase  MBI Fermentas 
Tango Buffer +/- BSA  MBI Fermentas 
Taq-buffer peqlab  laboratories 
Taq-DNA-polymerase  peqlab laboratories 
Water HPLC grade  Sigma Chemical CO. 
 
4.4  Oligonucleotides for cloning 
Name Sequence  Cloning  construct 
BamH1_R1-SD2_F           GGG CCC GGA TCC CCA TTT CGC AAA 
GCT CAG ATT GGT 
pAcGP67-B-SD234-H10 
BamH1-His 10-B               GAT CGG TGA TGG TGG TGA TGA TGG 
TGA TGG TGA TGG 
N-terminal His10 insertion 
BamH1-His 10-F               GAT CCC ATC ACC ATC ACC ATC ATC 
ACC ACC ATC ACC 
N-terminal His10 insertion 
His10 EcoRI F  AAT TCC ATC ATC ACC ATC ACC ATC 
ATC ATC ACC ATT 
C-terminal His10 insertion 
His10 EcoRI R   AAT TAA TGG TGA TGA TGA TGG TGA 
TGG TGA TGA TGG 
C-terminal His10 insertion 
His10_PstI GG  GGG  CTG CAG TTA ATG GTG ATG 
ATG ATG GTG ATG G 
pAcGP67-B-ifnar1-EC-H10 
IFNLR SD4 EcoR1 Z 
PstI 
CGC GCG CTG CAG TTA GAA TTC GTT 
GGC TTC TGG GAC CTC CAG 
pAcGP67-B-SD123-LRD2 
IL-10R2_EcoRI_R GCG  CGC  GAA TTC TTT GAC CGT TTC 
GTC ATG GGT TGT 
pAcGP67-B-SD123-IL10R2D2
pAcGP67-B_R1EC CCC  CCC  GGA TCC AAA AAT CTA AAA 
CCT CAA AAA GTA GAG 
pAcGP67-B-ifnar1-EC-H10 
R1 EcoR1 Z PstI  CGC GCG CTG CAG TTA GAA TTC TTT 
AGA GGT ATT TCC TGG TTT 
pAcGP67-B-ifnar1-EC-EcoRI 
R1-I (PPPEN)Z_1              CCC CCC CTG CAG TCA ATT TTC TGG 
TGG AGG TAG TTC ATT 
pAcGP67-B-H10-SD12 
R1-II-F                               CCC CCC AGG ATC CGA AAT GAA CTA 
CCT CCA CCA GAA 
pAcGP67-B-SD34-H10 
R1-SD3_BZ_PstI   CCC GGG CTG CAG TTA GTT AAA GAC 
TGG AGG AAG TAG GAA 
pAcGP67-B-H10-SD123 
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SD123 EcoRI Z PstI  CGC GCG CTG CAG TTA GAA TTC GTT 
AAA GAC TGG AGG AAG TAG GAA 
pAcGP67-B-SD123-H10 
 
4.5  Oligonucleotides for mutagenesis 
Mutation Primer  sequence 
Y70A  AAG CTG AAT GTT GCT GAA GAA ATT AAA 
R76A  GAA ATT AAA TTG GCT ATA AGA GCA GAA 
E111A  CAT TTA GAA GCT GCA GAT AAG GCA ATA 
K113A  GAA GCT GAA GAT GCG GCA ATA GTG ATA 
W129A  GAT AGT GTT ATG GCG GCT TTG GAT GGT 
F136A  GAT GGT TTA AGC GCT ACA TAT AGC TTA 
N155T  GAA AGG ATT GAA ACT ATT TAT TCC AGA 
L247A  CCT GGA AAC CAT GCG TAT AAA TGG AAA 
W250A  CAT TTG TAT AAA GCG AAA CAA ATA CCT 
K251A  AAC CAT TTG TAT AAA TGG GCA CAA ATA CCT GAC TGT GAA 
D298A  GAG ATA AAG TTT GCT ACT GAA ATA CAA 
N368D  GTT ACA GTT CCT GAT TTG AAA CCA CTG 
 
4.6 Chromatography  equipment 
Name Company 
Aekta Explorer  Amersham Pharmacia 
Aekta Prime  Amersham Pharmacia 
Amicon Ultra 0.5 and 15 (5kDa cut off)  Fisher Scientific 
HisTrap 1ml  Amersham Pharmacia 
HiTrap Chelating (1 ml and 5 ml)  Amersham Pharmacia 
HiTrap Sepharose Q (1 ml)  Amersham Pharmacia 
Sepharose Q  Amersham Pharmacia 
SMART Chromtography System  Amersham Pharmacia 
Superdex 200 HiLoad 16/60  Amersham Pharmacia 
Superdex 200 Hiload 26/60  Amersham Pharmacia 
Superdex 200 HR 10/30  Amersham Pharmacia 
Superdex 200 PC 3.2/30  Amersham Pharmacia 
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4.7  Buffers and solutions for purification and binding assays 
Buffer Composition 
IMAC dialysis buffer  50 mM Tris-HCl, pH 8 
  200 mM NaCl 
IMAC running buffer  50 mM Tris-HCl, pH 8 
  500 mM NaCl 
IMAC elution buffer  50 mM Tris-HCl, pH 8 
  500 mM NaCl 
  500 mM Imidazole 
IMAC stripping buffer  1 M NaCl 
  50 mM EDTA pH 8 
IMAC metal loading solution  20 mM ZnSO4
Size exclusion 
chromatography buffer 
20 mM Tris-HCl, pH 8 
200 mM NaCl 
RIfS running buffer  20 mM Hepes, pH 7.5 
  150 mM NaCl 
RIfS imidazole buffer  50 mM Tris-HCl, pH 7.5 
  500 mM NaCl 
  500 mM Imidazole 
RIfS metal loading buffer  20 mM Hepes, pH 7.5 
  150 mM NaCl 
  15 mM NiSO4
RIfS stripping buffer (HBS)  200mM EDTA pH 8 
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5 Methods 
5.1 Molecular  Biology 
5.1.1 Overview 
For expression of ifnar1-EC and several sub-fragments in Sf9 insect cells, genes of 
interest were cloned into the transfer vector pAcGP67-B via the restriction sites BamHI and 
PstI. The gene of mature ifnar1-EC (amino acids from KNL until TSK) with and without a C-
terminal decahistidine-tag was amplified via PCR from an ifnar containing vector (provided 
from Gilles Uzé, CNRS Montpellier), subsequently digested and cloned into the transfer 
vector. The same was done to get SD34-H10 and SD234-H10. An additional N-terminal 
extension ADLGS is expected from the cleavage site of the gp67 secretion sequence in the 
vector. 
SD1234-DT was generated by inserting a linker coding for an H10-tag at the N-
terminus of SD1234-H10 into the BamHI site (Figure 20), resulting in a total N-terminal 
extension of ADLGSH10RS. This linker was designed so that only the N-terminal BamHI site 
was retained. The sub-fragments H10-SD12 and H10-SD123 and also H10-SD1234 were 
subcloned based on this SD1234-DT construct. 
5.1.2  Polymerase Chain Reaction  
The Polymerase Chain Reaction (PCR) was used for amplifying certain gene 
sequences for cloning or further analysis. To provide Ifnar1-EC and different sub- fragments 
the following PCR-mix was prepared: 
Forward-primer (100 pM)  1 µl 
Reverse-Primer (100 pM)  1 µl 
Template    1-5  ng 
dNTPs (10 mM)    2 µl 
10x PCR-Buffer (-MgSO4) 5  µl 
MgSO4 (25 mM)    8 µl 
DNA-polymerase (1 U/µl)  3 µl 
Adjusted with HPLC-H2O to 50 µl 
 
To prepare PCR products for cloning a high fidelity polymerase like Pwo polymerase 
was used. In case of analytical PCR Taq polymerase was used. Depending on the expected 
length of PCR products elongation time varies in the following program: 
1. Initial Denaturation   95 °C, 2 min 
2. Denaturation    95 °C, 1 min 
3. Annealing      55 °C, 1 min 
4. Elongation      72 °C, 2 min/kb for Pwo, 1 min/kb for Taq 
5. Final Elongation    72 °C, 10 min 
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Step 2, 3 and 4 were repeated 25-30 times. 5 µl of the PCR were analyzed by 
agarose gel electrophoresis. If the expected band appeared on the gel the DNA was purified 
by PCR purification kit (Qiagen AG) and stored at -20 °C until restriction. To verify proper 
gene insertion into a cloning vector, bacteria colonies could be used as templates for PCR. 
After bacteria were suspended with a glass tip into the PCR mix (containing Taq polymerase) 
the reaction was started (35 cycles).  
5.1.3 DNA  preparation 
Plasmid DNA for sequencing was isolated by Nucleospin mini kit (Macherey & Nagel 
GmbH & Co. KG, Germany). DNAse contaminations were observed in these preparations, so 
mini plasmid DNA was not used for restriction analysis or co-transfection with virus DNA. 
Midi-DNA prepared by Nucleobond midi kit (Macherey & Nagel) was used for restriction 
analysis and for co-transfection with Baculogold-DNA. DNA concentration and purity were 
determined by absorbance at 260 nm and 260/280 nm absorbance ratio (ideal ratio: 1.8). 
5.1.4  Restriction of DNA 
For all cloning procedures DNA, either plasmids or inserts from PCR, were digested 
with restriction endonucleases. In general the amount of restriction enzyme and incubation 
time were adapted to gain a 10-20-fold over digestion. Buffers for single or double digestions 
correspond to the recommendations of the manufacturer (New England Biolabs Inc. and MBI 
Fermentas). Additionally restricted vector DNA was dephosphorylated for the final 30 min by 
adding calf intestine alkaline phopatase (CIAP). After checking restriction by agarose gel 
electrophoresis, the DNA was purified by using the PCR purification kit (Qiagen AG). 
5.1.5 Ligation 
Restricted insert and vector DNA were quantified by agarose gel electrophoresis to 
apply a molar ratio of 3-5:1 (insert : vector). After mixing DNA 2 µl, reaction-buffer and 1 µl 
T4-Ligase were added. Subsequently the reaction mix was adjusted with HPLC-H2O to 20 µl 
volume and incubated for 2-4 h at room temperature. 
5.1.6 Transformation 
150µl of competent E. coli TG-1 cells were thawed on ice and mixed with 10µl of 
ligation reaction mix. After incubation on ice for at least 30 min cells were plated on pre-
warmed agar plates supplemented with 100 µg/ml ampicillin.  
5.1.7  Site Directed Mutagenesis 
For generating mutants ligase chain reaction (LCR) technique was used. In contrast 
to PCR only one primer carrying the chosen point mutation annealed to the template 
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(pAcGP67-B-ifnar1-H10). The high fidelity DNA-polymerase Pwo synthesized the whole 
complementary strand which is subsequently ligated by a thermo stable ligase (Amp-ligase). 
Thus one single stranded, circularized DNA strand was produced per cycle, which is not an 
exponential amplification like in PCR. A problem of this method was the size of the template 
(11 kb) making long elongation times and sometimes the addition of Taq polymerase 
necessary.  
Before LCR the primer was phosphorylated (section 5.1.8). 150-200 ng plasmid DNA 
was applied as template. In contrast to PCR elongation time of 20 min, elongation and 
ligation temperature of 65 °C and 25 cycles were used: 
150-200ng Template-DNA   
4 µl     Primer (phosphorylated) 
5µl    dNTP-Mix (2 mM) 
2.5 µl    NAD
+ (10 mM) 
5 µl    10 x Puffer (incomplete) 
8 µl    MgSO4 (25 mM) 
3 µl    Pwo polymerase (1 U/µl) 
2 µl    Amp-Ligase (5 U/µl) 
ad 50µl  HPLC-H2O 
 
After purification by the PCR purification kit DNA was digested by DpnI, which 
specifically cuts methylated DNA. While synthesized DNA was not affected by DpnI, 
maternal template DNA was removed and only single stranded DNA carrying the chosen 
mutation should survive this procedure. After DpnI treatment as described by the 
manufacturer E. coli TG-1 cells were transfected with the reaction mix. Colonies were chosen 
for DNA preparation followed by sequencing. 50-75% of the picked clones carried the 
mutation and were used for co-transfecting Sf9. 
5.1.8 Oligonucleotide  Insertion 
To fuse defined sequences to the C- or the N-terminus of a protein, for example a 
histidine-tag, a double stranded oligonucleotide carrying the sequence was inserted into the 
cloning vector. The oligos were designed to fit into a restriction enzyme cutting site in frame 
of the gene (Figure 20B). By insertion the former cutting site was destroyed to enable cloning 
of the whole construct into other vectors (Figure 20C).  
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pAcgp67B GGATCC R1EC
pAcgp67B CCTAGG R1EC
pAcgp67B G
pAcgp67B CCTAG
GATCC R1EC
GR 1 E C
GATCC CATCACCATCACCATCATCACCACCATCAC C
G GTAGTGGTAGTGGTAGTAGTGGTGGTAGTGGCTAG
BamHI
pAcgp67B G
pAcgp67B CCTAG
GATCC R1EC
GR 1 E C
GATCC CATCACCATCACCATCATCACCACCATCAC  C
G GTAGTGGTAGTGGTAGTAGTGGTGGTAGTGGCTAG
BamHI
BamHI
A
B
C
pAcgp67B GGATCC R1EC
pAcgp67B CCTAGG R1EC
pAcgp67B G
pAcgp67B CCTAG
GATCC R1EC
GR 1 E C
GATCC CATCACCATCACCATCATCACCACCATCAC C
G GTAGTGGTAGTGGTAGTAGTGGTGGTAGTGGCTAG
BamHI
pAcgp67B G
pAcgp67B CCTAG
GATCC R1EC
GR 1 E C
GATCC CATCACCATCACCATCATCACCACCATCAC  C
G GTAGTGGTAGTGGTAGTAGTGGTGGTAGTGGCTAG
BamHI
BamHI
pAcgp67B GGATCC R1EC
pAcgp67B CCTAGG R1EC
pAcgp67B GGATCC R1EC
pAcgp67B CCTAGG R1EC
pAcgp67B G
pAcgp67B CCTAG
pAcgp67B G
pAcgp67B CCTAG
GATCC R1EC
GR 1 E C
GATCC R1EC
GR 1 E C
GATCC CATCACCATCACCATCATCACCACCATCAC C
G GTAGTGGTAGTGGTAGTAGTGGTGGTAGTGGCTAG
GATCC CATCACCATCACCATCATCACCACCATCAC C
G GTAGTGGTAGTGGTAGTAGTGGTGGTAGTGGCTAG
BamHI BamHI
pAcgp67B G
pAcgp67B CCTAG
pAcgp67B G
pAcgp67B CCTAG
GATCC R1EC
GR 1 E C
GATCC R1EC
GR 1 E C
GATCC CATCACCATCACCATCATCACCACCATCAC  C
G GTAGTGGTAGTGGTAGTAGTGGTGGTAGTGGCTAG
GATCC CATCACCATCACCATCATCACCACCATCAC  C
G GTAGTGGTAGTGGTAGTAGTGGTGGTAGTGGCTAG
BamHI BamHI
BamHI
A
B
C
 
Figure 20   Schematic of an N-terminal H10-oligoinsertion into a BamHI site. The vector 
pAcGP67-B-ifnar1-EC is cut (A), annealed to the insert (B) and ligated (C). 
 
In this work either the BamHI site for N-terminal His10-tag or EcoRI and PstI sites for 
C-terminal His10-tag insertion were used. As a representative example the procedure of a 
His10-tag insertion into the BamHI site is described: 
Annealing of the oligonucleotides 
BamHI-His10-Forward (100 pM)    1 µl 
BamHI-His10-Backward (100 pM)    1 µl 
PNK–Buffer  A     10  µl 
HPLC-H2O      8 8   µ l  
1 min 95 °C, 10min 60 °C 
 
Insert phosphorylation 
BamHI-His10     20  µl 
ATP (50 mM)          1 µl 
PNK-buffer  A         2  µl 
PNK          1   µ l  
HPLC-H2O          1   µ l  
2 h 37 °C, 20 min 80 °C 
 
Vector restriction and dephosphorylation 
pAc-R1H10 (500 ng/µl)    10 µl 
BamHI-buffer         2  µl 
BamH I             2  µ l  
CIAP (for the last 30 min)      1 µl  
4 h 37 °C, 20 min 80 °C, purification by PCR purification kit (Qiagen) 
 
Ligation 
pAc-R1H10 restriction         1 µl 
Insert (1:100)          0.5 µl 
Ligase-buffer              2 µl 
T4-Ligase             1 µl 
HPLC-H2O       15.5  µl 
2-4 h at room temperature 
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The ligation mixture was used for E. coli transformation as described in section 5.1.6. 
Proper insertion and orientation were checked by colony PCR using BamHI-His10-Forward 
in combination with a standard backward sequencing primer (section 5.1.2). Positive clones 
were picked and mini DNA was sequenced. 
5.1.9 Sequencing 
All sequencing services were done by Scientific Research and Development GmbH. 
As sequencing primers pAc-SeqF, pAc-SeqR and sometimes mutation primers were used. 
Sequences were checked with BioEdit Sequence Alignment software. 
5.2  Insect cell culture 
5.2.1  Monolayer culture of Sf9 cells 
Monolayer cultures of Spodoptera frugiperda (Sf9) insect cells were grown at 27 °C in 
SF900 II medium (10 U/ml penicillin, 0.1 mg/ml streptomycin, 0.2% pluronic acid and 
5%  fetal calf serum). Healthy cells generally doubled every 18-24 hours and were 
subcultured when a closed confluent layer occurred (3 times a week). For a passage medium 
and floating cells were replaced by fresh, pre-warmed medium. Cells with passage numbers 
>55 were discarded. 
5.2.2  Shaking culture of Sf9 cells 
For expression cultures up to a volume of 500 ml Sf9 cells were cultivated in shaker 
flasks at 27 °C. The cultures were incubated in less than 50% of the total flask volume and 
under defined shaking conditions (<200 ml at 110 rpm, >200 ml at 60 rpm). To get cells in 
the dynamic growth phase cell density was kept between 0.3x10
6 cells/ml and 3x10
6 cells/ml. 
Cells in the stationary phase (>5 x10
6 cells/ml) were discarded. 
5.2.3  Co-transfection of Sf9 cells 
The co-transfection procedure was carried out as described in the Baculogold manual 
(BD Bioscience Pharmingen). To safe expensive linearized viral DNA, a scale-down protocol 
was established for 1/5 of the original DNA amount: 
¾ 0.2x10
6 Sf9 cells were seeded into a 12-well-culture plate (~30% confluence).  
The volume per well was at least >500µl to prevent cells from drying out. The 
procedure was continued until cell attachment. 
¾  1.25 µl (0.5 µl) linearized Baculogold-DNA and 0.5 µg plasmid (1-5 µl from 
Midi preparation) were mixed and incubated for 5 min.  
¾  Medium was replaced by 250 µl transfection buffer A (BD Bioscience). 
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¾  250 µl transfection buffer B (BD Bioscience) was mixed with the DNA. 
¾  Buffer B was carefully added to cells drop by drop, after 2-3 drops the plate 
was slightly moved back and forth to facilitate efficient mixing. Under the 
microscope small crystals were observed after a few minutes. 
¾  The culture plate was prevented from drying out by covering with parafilm and 
incubated for 4-5 hours at 27 °C. 
¾  Cells were washed two times with 1 ml SF900 II medium. 
¾  The recommended incubation time of 4-5 days was expanded to 8-9 days to 
increase virus titer. After this time 500µl of the supernatant (P0) containing 
viruses was added to a fresh 5 ml monolayer culture and incubated additional 
7 days (P1). After 2-3 days signs of infection should be observed (proliferation 
stop, size increase and floating, Figure 21B).  
¾  Cells were removed by centrifugation and the supernatant was stored in 
darkness at 4 °C or alternatively shock frozen at -80 °C. For preparation of P2 
again 500 µl of P1 were added to a fresh 10 ml monolayer culture.   
AB
 
Figure  21    Comparison of infected and uninfected Sf9-monolayers. A: Uninfected cells. B: 
Infected cells 3 days after infection with 1% P2. 
5.2.4  Infection cultures for protein production 
For protein production cells were grown in SF900 II medium supplied with FCS at 
27 °C. To avoid mechanical stress 1 liter Fernbach flasks were used at 60 rpm to cultivate 
250-500 ml cells. When a cell density of 2-2.5x10
6 cells/ml was reached the culture was 
infected with 1 % virus amplification P2. After an incubation time of 3-4 days cells were 
harvested by centrifugation (5000 rpm, 5min) and the supernatant was shock-frozen in liquid 
nitrogen until protein purification.  
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5.3  Protein purification and characterization 
5.3.1 Overview  of  proteins 
In order to investigate interactions between extracellular domains of ifnar and ligands 
all proteins were purified to homogeneity and well characterized with respect to concentration 
and stability. IFNα2 and ifnar2-EC were expressed in E. coli, refolded from inclusion bodies 
and purified by anion exchange and size exclusion chromatography [86]. The IFNα2 mutant 
S136C was site-specifically labeled with Alexa Fluor 488 (AF-488) maleimide (Molecular 
Probes), and was further purified by desalting and a final step of anion exchange 
chromatography. Maltose binding protein (MBP) containing an N-terminal His10-tag was 
expressed in E. coli TG-1 transformed with the pMAL-c2x vector (New England Biolabs). 
Subsequently it was purified from cytoplasm via IMAC and SEC as described below. The 
purification of ifnar1-EC and all corresponding sub-fragments and mutants are described in 
more detail in the following chapters. 
5.3.2  Immobilized metal chelate affinity chromatography (IMAC) 
Sf9 supernatant contained several molecules acting as chelators which were able to 
remove metal ions from the IMAC-columns. After adjusting the supernatant to dialysis 
conditions (20 mM Tris/HCl, pH 8.0, 200 mM NaCl), it was dialyzed twice for at least 3 h and 
once over night against 4 L dialysis buffer. After removal of cell fragments and precipitates by 
centrifugation (15000 rpm, 15 min) the solution was ready for IMAC procedure. 
Before every run, an IDA-column (5 ml HiTrap Chelating, Amersham Pharmacia) was 
conditioned with 25 ml stripping buffer (50 mM EDTA, pH 8.0, 1 M NaCl), 25 ml water, 50 ml 
ZnSO4 (20 mM) and 25 ml running buffer (50 mM Tris, pH 8.0, 500 mM NaCl). The resin was 
loaded with a flow rate of 5 ml/min and 20 mM imidazole to prevent unspecific binding. After 
loading the column was washed again with 40 mM imidazole until the baseline was stable. 
The protein was then eluted by an imidazole gradient (length: 20 ml, target: 500  mM 
imidazole, fraction size: 2 ml). Protein-containing samples were identified by SDS-PAGE, 
pooled and stored at 4 °C until size exclusion chromatography. 
5.3.3  Size exclusion chromatography (SEC) 
To remove aggregates and imidazole and also to adjust protein samples to defined 
buffer conditions (20 mM Tris/HCl, pH 8.0, 200 mM NaCl) size exclusion chromatography 
(SEC) was used. Since deca-histidine-tags were observes to carry metals from IMAC, 
samples were adjusted to 1mM EDTA and centrifuged (5 min, 13000 rpm, RT) before 
injection. Depending on sample volume different columns were used (Table 2). In analytical 
SEC samples were centrifuged after thawing and subsequently injected. 
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Table 2   Columns for size exclusion chromatography 
Column name  Flow rate 
max.  
Pressure 
max. 
Sample 
volume 
Exclusion 
volume 
Bed volume
Superdex 200 PC 3.2/30  100 µl/min 1.5 MPa 50 µl ~ 0.8 ml  ~  2.4 ml
Superdex 200 HR 10/30  500 µl/min 1.5 MPa 500 µl ~ 7.5 ml  ~ 21 ml
Superdex 200 HiLoad 16/60  1.5 ml/min 0.5 MPa 4.0 ml ~ 50 ml  ~ 122 ml
Superdex 200 Hiload 26/60  4 ml/min 0.5 MPa 10.0 ml ~ 110 ml  ~ 320 ml
5.3.4 Protein  concentration 
After size exclusion chromatography protein fractions were pooled and concentrated 
by ultrafiltration (equilibrated Amicon ultra 15) at 3000 rpm until volume reduction to <3 ml. 
Membranes were washed after usage with sterile water and stored at 4  °C for several 
months. 
5.3.5  Protein concentration determination 
Protein concentrations were determined by UV/Vis-spectroscopy. Taking the 
theoretical extinction coefficients (e.g. 84.000 M
-1cm
-1 for ifnar1-EC determined with 
ProtParam Software from expasy.ch) into account, the concentration was calculated. As a 
representative example a UV/Vis-spectrum of ifnar1-H10 is shown (Figure 22), also 
containing the expected “tryptophane shoulder” at 290 nm. Proteins were then aliquoted and 
shock-frozen at 10-60 µM concentration in liquid nitrogen.  
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Figure 22  UV/Vis-Spectrum of a 10 µM ifnar1-EC sample in TBS buffer after SEC and spin 
concentration.  
5.3.6 Deglycosylation   
Proteins expressed and secreted from Sf9 insect cells were expected to be N-
glycosylated. Ifnar1-EC carries 9 potential N-glycosylation sites. To analyze protein 
glycosylation the deglycosylation enzymes EndoH and PNGaseF were used. 
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Analytical deglycosylation was done under denaturing conditions. Samples with 20 
µM concentrations were incubated at 100 °C and 1% SDS / 100 mM DTT for 10 min to unfold 
and reduce the protein. After cooling and addition of NP40 (for SDS inhibition) enzymes were 
added to deglycosylate the samples as described in the manufacturer’s manual. 
Deglycosylation efficiency was then investigated by SDS-PAGE.  
Preparative deglycosylation using PNGaseF (New England Biolabs) was carried out 
directly in protein sample buffer according to the instructions of the manufacturer (8h at room 
temperature). These samples were used for analytical size exclusion chromatography and 
binding assays to verify activity of deglycosylated protein. 
5.3.7 Western-Blot 
To detect His-tagged proteins Western-Blot analysis was performed as described 
below by using an NTA conjugate of alkaline phosphatase. 
¾  Blotting the SDS-PAGE for 60-90 min at 100 mA to a nitrocellulose membrane 
¾  Washing 3x5 min with PBS  
¾  Blocking accessible binding sites for 1 h with 3% BSA in PBST  
¾  Washing 3x10 min with PBST 
¾  1 h incubation with Ni-NTA-AP-conjugate (1:1000 in TBST)  
¾  Washing 3x10 min with TBST  
¾  Washing 10min with AP-buffer  
¾  Developing with 10 µl NBT and 60 µl BCIP in 20 ml AP-buffer until blue color 
appeared 
¾  Reaction was stopped by addition of water 
 
5.3.8 CD-Spectroscopy 
For CD spectroscopy, proteins at 20-40 µM concentration were extensively dialyzed 
against 20 mM Pi pH 8.0, 150 mM sodium fluoride. Circular dichroism spectra were recorded 
on a Jasco J-810 CD spectrometer equipped with a Jasco PTC-423S Peltier temperature 
control system using quartz cuvettes with 0.2 mm path lengths at 22 °C. Secondary structure 
composition was calculated using the estimation software Jasco Spectra Manager Version 
1.53.00. 
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5.4  Protein interactions on surfaces 
5.4.1 Detection  system 
Lipid bilayer assembling, receptor immobilization protein interactions and surface 
conditioning were monitored by Rif(S). This label-free detection technique monitors binding 
on the surface of a thin silica interference layer [96, 97], and therefore was compatible with 
fluorescence detection. In this study two different set-ups were applied. In one set-up the 
shift of the interference maximum was used as read out. In the other set-up light intensity at 
a certain wave length was correlated with mass deposition.  
Binding curves were obtained from the shift of the interference spectrum of the silica 
layer: a shift of 1 nm corresponds to approximately 1 ng protein per mm² on the surface. 
Measurements were carried out in a flow chamber with an acquisition rate of 1 Hz under 
continuous flow-through conditions as described [96, 97].  Binding of fluorescence-labeled 
proteins was monitored by TIRFS using a home-built setup [94]. A 25 mW argon ion laser 
was used for fluorescence excitation at 488 nm. Typically a low excitation power of 2-3 mW 
focused onto an area of 1-2 mm²  was used in order to minimize photo bleaching. 
Fluorescence was collected by an optical fiber and detected by a photomultiplier tube 
through a band pass filter. The same transducer slides as for RIfS detection were used as 
substrates, and all processes on the surface were monitored simultaneously by single-
wavelength RIfS detection at 800 nm. Continuous flow-through conditions were maintained 
for all experiments. Data were acquired with a time resolution between 1.5 s and 16 s 
depending on the kinetics of the process.  Photobleaching was minimized by closing the 
shutter of the excitation source between the measurements. 
5.4.2 Vesicle  preparation and bilayer fusion 
Before vesicle preparation Hamilton syringes were washed extensively with methanol 
and chloroform. SOPC in chloroform was mixed with 1–5 mol% of a bis-NTA chelator lipid. 
After removing the solvent by vacuum evaporation (20 min) and resuspension into HBS 
buffer (15 min), small unilaminar vesicles (SUV) were prepared by sonication (15 min on ice). 
The transducer surface was incubated for at least 15 min in freshly prepared mixture of one 
part 30% (v/v) hydrogen peroxide and two parts concentrated sulfuric acid. After extensive 
washing with water, the transducer was mounted immediately into the flow cell. SUVs at a 
concentration of 250 µM were injected and bilayer formation was followed by RIfS-detection 
(Figure 23). Vesicle fusion should appear rapidly with a signal intensity of 5 nm. For every 
measurement the bilayer was conditioned by sequential 50 sec injections of 500 mM 
imidazole pH 8.0, 200 mM EDTA pH 8.0, and 15 mM NiSO4 (in HBS), 270 µl each (Figure 
23B). Bilayers could be used for one day of measurements or until an air bubble occurred. 
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Figure 23   A: Cartoon of vesicle fusion to a glass surface. B: Detection of bilayer assembly (BL) 
and the injections of imidazole (I), EDTA (II) and Ni
2+ (III) as detected by RIfS. 
5.4.3 Protein  interaction  experiments 
For probing individual interactions proteins were immobilized via their H10-tag to a 
PEG polymer brush carrying bis- or tris-NTA head groups (non-fluid support). To investigate 
ternary complex assembly, receptors were co-immobilized on a lipid bilayer to achieve lateral 
mobility of the individual proteins in plane of the membrane (fluid support). Protein 
immobilization and ligand binding was always monitored by RIfS, additionally fluorescence 
labeled samples were also simultaneously detected by TIRFS. Depending on the targeted 
surface concentration (signal intensities 0.2-2 nm), receptors at concentrations between 
50 nM and 300 nM were injected for 470 sec. In order to check proper attachment of the 
receptors after every injection the surface was washed for 100-200 s with a flow rate of 1 
ml/min. Depending on the ligand and the goal of the experiment different injection (50 or 220 
s) and washing times were used. For studying IFNβ, which is known to bind metal ions, 
excess of coordination sites was blocked by injection of 3-5 µM MBP-H10 before binding 
experiments. After every binding experiment either lipid or covalent surfaces were 
conditioned as described above (section 5.4.2). 
  
 48   Results 
6 Results 
6.1 Protein  Biochemistry 
6.1.1  Purification of ifnar1-EC and sub-fragments 
Ifnar1-EC and all sub-fragments and mutants were expressed in Sf9 cells with an N-
terminal secretion sequence of the baculovirus protein gp67. It was expected that the target 
protein was secreted via the secretory pathway into the medium. This secretion process was 
required for disulfide-bond formation and probable glycosylation. Both features were 
necessary to enable proper folding and protein stability. Proteins were extracted from the 
medium by using their C- or N-terminal decahistidine-tag for immobilized metal affinity 
purification (IMAC). As a representative example for all constructs the purification of ifnar1-
EC with a C-terminal H10-tag by using a Zn
2+-IDA resin is shown in Figure 24. Ifnar1-EC 
eluted at ~180  mM  imidazole (Figure 24A) and SDS-PAGE analysis demonstrated the 
successful extraction as well as the efficient purification to homogeneity (Figure 24B).  
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Figure 24   IMAC of Sf9 supernatant containing ifnar1-EC. A: Chromatogram of the imidazole 
gradient. B: SDS-PAGE of collected elution fractions (1-10) and applied supernatant 
(SN). 
 
In the next step, aggregates as well as imidazole were removed by size exclusion 
chromatography. Ifnar1-EC eluted in a symmetric peak at a retention volume expected for 
the monomer (Figure 25A). In SDS-PAGE, a molecular mass of approximately 57 kDa was 
observed (Figure 25B), indicating glycosylation of ifnar1-EC in the insect cells. From 
analytical SEC it was concluded that ifnar1-EC was monomeric by taking the retention 
volume of ifnar2-EC and IFNα2 into account (Figure 26). In order to identify ifnar1-EC as the 
purified protein, a Western-Blot detecting the H10-tag was carried out. All fractions of a 
monomer peak determined from SDS-PAGE led to a corresponding band in Western-Blot 
(Figure 25C). Also Western-Blot analysis with anti-ifnar1 antibodies confirmed the identity of 
the purified protein.  
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Figure 25   Size exclusion chromatography (Superdex 200 HR 26/60) of ifnar1-EC from IMAC: 
Chromatogram (A) and corresponding SDS-PAGE (B); 1-11, fractions; M, Marker; 
IMAC, loaded sample. C: Western-Blot of an ifnar1-EC monomer peak from SEC for 
His-tag detection with Ni-NTA-AP conjugate. 
 
The purified ifnar1-EC was shock-frozen in liquid nitrogen and stored at -80 °C. After 
two cycles of freezing and thawing < 5 % aggregation was observed in analytical SEC 
(Figure 26). Thus a very efficient purification strategy for ifnar1-EC purification, ending up 
with a purity of > 95% and a yield of stable, monomeric protein of ~ 10 mg/l, was established.  
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Figure 26  Analytical SEC (Superdex 200, 10/30 ) with ifnar1-EC after two cycles of freezing and 
thawing. V0: Exclusion volume; Vc: Bed volume. 
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This strategy was successfully applied to the purification of all sub-fragments and 
mutants (Figure 27). The sub-fragments as well as the double tagged ifnar1-EC (SD1234-
DT) were purified equally to the wild-type protein in yields of 5-10 mg/l cell culture. Since all 
sub-fragments were glycosylated, monomeric in gel filtration and stable, they were used for 
further biochemical characterization and binding experiments.  
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Figure  27    SDS-PAGE of the purified sub-fragments after IMAC and size exclusion 
chromatography under reducing conditions. In agreement with the sub-fragment 
definition ifnar1-EC is named SD1234-H10. 
 
The replacement of SD4 by homologous receptor domains was more critical (Figure 
28). SD123-IL10R2D2 was > 90 % aggregated as demonstrated by SEC (Figure 28B) and 
not used for any further experiments. Fusing this domain to SD123 seemed to prevent proper 
folding. Interestingly SD123-IL10V1V2, which differs from SD123-IL10R2D2 by two short 
ifnar1-EC sequences (3.5.2), was purified in amounts equal to wild-type protein (Figure 28B, 
C). SD123-LRD2 was purified as a dimer, probably caused by a third cysteine on LRD2 
(Figure 28B, C). However, this construct was stable and active and therefore used for 
binding experiments. 
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Figure  28  A: Cartoon of the ifnar1-EC constructs with SD4 substituted with homologous 
receptor domains of IL10 (IL10R2D2 and V1V2) and IFNλR (LRD2). B: SEC of 
SD123-IL10V1V2 (blue), SD123-IL10R2D2 (green) and SD123-LRD2 (red). C: 
Corresponding SDS-PAGEs under oxidizing conditions (Fractions: 1-10, M: Marker). 
6.1.2 Protein  deglycosylation 
For purified ifnar1-EC a single, yet broadened band corresponding to a molecular 
mass of approximately 57 kDa was observed in SDS-PAGE in contrast to a calculated mass 
of 49 kDa. This difference suggested substantial glycosylation of the protein. In order to 
identify the type of glycosylation, the deglycosylation enzymes EndoH and PNGaseF were 
used. While EndoH cleaves specifically hybrid and high mannose structures (Figure 29A), 
PNGaseF cleaves all glycosylation types including the complex type (Figure 29B). For 
EndoH no degycosylation of ifnar1-EC was observed, but removal of the glycans with 
PNGaseF yielded a protein with an apparent molecular mass of 49 kDa corresponding to the 
expected molecular mass (Figure 29D, E).  
In an additional SDS-PAGE analysis the formation of disulfide bonds was 
investigated. Under non-reducing conditions the band of deglycosylated ifnar1 was shifted to 
a lower molecular mass compared to the reduced protein, indicating internal disulfide bonds 
formation (Figure 29E) leading to a faster migration in SDS-PAGE. All these results led to the 
conclusion, that ifnar1-EC was oxidized, site specifically glycosylated and secreted into the 
medium via the secretory pathway of Sf9. 
For the sub-fragments similar shifts as well as band broadening and even multiple 
bands were observed (Figure 29C). Significant shifts between SD123 and SD234 as well as 
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SD12 and 34 were observed, suggesting different grades of glycosylation as predicted in 
Table 3. For all proteins the apparent molecular mass shifted to the expected mass after 
PNGaseF treatment (Table 3) confirming a complete expression of the sub-fragments. 
Interestingly also the small difference of 12 amino acids between the single and the double-
tagged ifnar1-EC could be detected by SDS-PAGE.  
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Figure 29   A, B: Schematic of EndoH (A) and PNGaseF (B) cleavage sites.  C, D: SDS-PAGE of 
the purified sub-fragments after IMAC and size exclusion chromatography without (C) 
and with PNGaseF treatment (D) under reducing conditions. E: SDS-PAGE of 
purified ifnar1-EC after deglycosylation with PNGaseF under non-reducing and 
reducing conditions in comparison to the non-deglycosylated protein. 
6.1.3  Further biochemical characterization 
Ifnar1-EC and sub-fragments were investigated by analytical SEC with and without 
deglycosylation. The rather broad, asymmetric peaks observed for the glycosylated proteins 
(Figure 30A) became more sharp and symmetric, and slightly shifted towards higher elution 
volumes after deglycosylation (Figure 30B). While no significant difference between ifnar1-
EC (SD1234-H10) and SD1234-DT was detectable, H10-SD123 was eluted with 
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substantially higher apparent molecular size than SD234-H10, despite the very similar 
apparent molecular mass observed in SDS-PAGE. This difference suggests a different 
spatial and possibly non-symmetrical arrangement of the Ig-like domains in these two 
proteins. Also between H10-SD12 and SD34-H10, a small, but reproducible and significant 
shift was observed, indicating a different structural organization of these to potential CBMs.  
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Figure 30  Analytical SEC of the purified sub-fragments before (A) and after deglycosylation with 
PNGaseF (B). Color coding as shown in the inset. 
 
In order to confirm proper folding the secondary structure was investigated by 
CD-spectroscopy (Figure 31). The anticipated secondary structure of mainly β-sheet (Table 
3) was confirmed for all sub-fragments by CD spectroscopy corroborating appropriate folding 
of the protein.  
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Figure 31   CD-spectrum of ifnar1-EC and sub-fragments for secondary structure analysis (color 
coding in the inset). 
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In Table 3 all results of the biochemical analysis for ifnar1-EC and its sub-fragments 
are summarized. For all the following binding experiments glycosylated proteins were used. 
 
Table 3   Biochemical properties of ifnar1-EC sub-fragments.  
Name ifnar1-H10  ifnar1-DT  SD12  SD34  SD123  SD234 
Sequence
1 K1-K409 K1-K409 K1-N207  E199-K409 K1-N311  P95-K409 
H10-tag
2 C C,  N N  C C,  N C 
Total no. of aa
3 424 436 224 226 326 325 
MM  (expected)  [98]  49.0 50.6 25.8 26.2 37.9 37.4 
MM
4 (found) [kDa]  57.3  -  31.1  29.4  45.3  42.2 
MM
5 (deglyc.) [kDa]
  49 50 29 30 40 39 
pot. glycos. Sites
6 9 9 5 4 7 5 
β-sheet/α-helix/RC
7 84/2/14 78/2/20 70/4/26  77/01/22 76/3/21  75/2/23 
1First and last amino acid accord to the predicted mature sequence. 
2Position of the decahistidine 
tag(s). 
3Number of amino acids including additional residues derived from cloning strategy and tag-
insertion. 
4,5The molecular masses were estimated from MALDI (for glycosylated proteins) and from 
SDS-PAGE (for deglycosylated proteins). 
6The potential glycosylation sites were predicted by 
NetNGlyc 1.0 Server. 
7The secondary structures were determined by CD-spectroscopy. 
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6.2  Dissection of interferon receptor assembling 
6.2.1  Stoichiometry of the IFN receptor complex in solution 
The formation of a stable complex with a 1:1:1 stiochiometry for recombinant ifnar1-
EC, ifnar2-EC and IFNβ was shown in analytical SEC [63]. Only in presence of ifnar2-EC this 
interaction was detectable. Thus a cooperative effect of ifnar2-EC was proposed. In order to 
investigate stoichiometry, affinity and possible cooperative effects in solution, the interactions 
between ifnar1-EC, ifnar2-EC and IFNα2/β were also analyzed by SEC. For IFNα2 either in 
complex with ifnar2-EC or alone no detectable interaction with ifnar1-EC could be detected 
up to µM concentrations (data not shown). This result indicated low affinity (KD ~ µM range) 
for the IFNα2/ifnar1-EC interaction, which prevents stable complex formation. In contrast to 
IFNα2, IFNβ was expected to have a higher affinity towards ifnar1-EC. IFNβ samples 
(formulated Rebif
®, 5-10 µg/ml) were supplied with additives (> 10 mg/ml HSA) stabilizing 
IFNβ for clinical applications, which made the detection at a wavelength of 280 nm very 
difficult. For monitoring specifically the receptor subunits, ifnar1-H10 and ifnar2-H10 were 
labeled through a tris-NTA-fluorescein conjugate. This conjugate stoichiometrically and 
stably interacts with a his-tag and enables detection at 490 nm (fluorescein absorbance). In 
parallel an IFNα2 mutant (IFNα2-HEQ) was used. On IFNα2-HEQ H57, E58 and Q61 were 
replaced by alanines leading to a 40-fold increased affinity towards ifnar1 comparable with 
that of IFNβ (personal communication with Gideon Schreiber).  
For IFNα2-HEQ as well as for IFNβ a stable binary complex with ifnar1-EC was 
detected (Figure 32A) and identified by SDS-PAGE (Figure 32B), which also confirmed the 
activity of the proteins. Interestingly only a minute shift of ifnar1-EC signal in SEC was 
observed for both IFNs. Thus IFN binding to ifnar1-EC did not seem to enhance the 
hydrodynamic radius significantly. Probably ligand binding compensated the increase of 
molecular weight by a structural arrangement of the sub-domain structure. However, a stable 
binary complex for ifnar1-EC with IFNβ as well as IFNα2-HEQ was clearly demonstrated. 
This result contradicted to the observation, that ifnar1-EC only interacted with IFNβ in the 
presence of ifnar2-EC [63]. Probably the minute shift between ifnar1-EC and the binary 
complex was not detected.  
Separately, isolated IFNα2-HEQ (~ 20 kDa) and ifnar2-EC (~ 25 kDa) eluted at the 
expected retention volume (Figure 32C). Ifnar2-EC together with IFNα2-HEQ shifted to a 
higher molecular weight, which agreed with a binary complex formation (~  45  kDa). 
Interestingly, ifnar1-EC showed a significant shift compared to this binary complex. The 
different molecular weights (57 kDa for ifnar1-EC, 45 kDa for ifnar2-EC-IFNα2) could not 
explain these different retention volumes. A probably more stretched structural arrangement 
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of the four sub-domains of ifnar1-EC in contrast to a more compact arrangement in the 
ifnar2-EC/IFNα2-HEQ complex was indicated. The retention volume of the ternary complex 
of IFNα2-HEQ/ifnar1-EC/ifnar2-EC was in agreement with the molecular weight expected for 
a 1:1:1 complex (~100 kDa, Figure 32). All three proteins in the complex were identified by 
SDS-PAGE (Figure 32D). In order to prepare quantitative amounts of the ternary complex, it 
was necessary to concentrate the mixture of ifnar1-EC/ifnar2-EC/IFNα2-HEQ (up to 100 µM). 
As a consequence aggregation was observed as a “shoulder” (Figure 32C). At this 
concentration aggregation was also observed separately for ifnar1-EC and ifnar2-EC (data 
not shown). Thus, this observation did not indicate a stoichiometry higher than 1:1:1.  
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Figure  32    Analytical SECs of complexes and individual proteins on a Superdex 200 3.2. A: 
Binary complex of IFNα2-HEQ, IFNβ and ifnar1-EC. The complex with IFNβ was 
detected at 490 nm via an NTA-fluorescein conjugate binding to the his-tag. B: SDS-
PAGE of the binary complex of ifnar1-EC/IFNα2-HEQ C: Ternary complex and 
individual proteins. D: SDS-PAGE of the ternary complex collected at 1.3 ml retention 
volume. 
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6.2.2  Interaction of ifnar2-EC with IFNα2 and IFNβ on solid support 
From analytical SEC different affinities for IFNα2 and IFNβ towards ifnar1-EC were 
qualitatively proposed. Also the proposed cooperative effect of ifnar2-EC on the 
ifnar1-EC/IFN interaction [63] has not been confirmed. Thus, in order to quantitatively 
investigate differences between individual IFNs with respect to stoichiometry, affinity and 
cooperativity, an in vitro binding assay is required. 
Binding of IFNα2 to immobilized tag-less ifnar2-EC without a his-tag (ifnar2-tl, i.e. tag-
less) has been studied before on different surfaces [93]. Here all receptor proteins were 
immobilized via their C-terminal deca-histidine-tags in a site-specific and oriented manner to 
the surface. To exclude any influence of this immobilization mode on the activity, individual 
interactions of immobilized ifnar2-EC with IFNα2 and IFNβ were probed on a PEG polymer 
brush carrying a multivalent chelator head group (Figure 33A). IFNα2 interacted specifically 
with ifnar2-EC (Figure 33B) and the stoichiometry as determined from the relative binding 
amplitudes was 1:1. Thus, stable and oriented tethering through a decahistidine-tag retained 
the protein fully functional on the surface. From concentration dependent binding curves, a kd 
value of 0.010 ± 0.002 s
-1, a ka value of (3 ± 1)·10
6 M
-1s
-1 and a KD value of 3 ± 1 nM were 
determined. These values are in excellent agreement with the values obtained for ifnar2-tl 
immobilized via monoclonal antibodies [93]. The association phase was significantly biased 
by mass transport limitation as indicated by the systematic deviation from the model (Figure 
33D). Also the dissociation phase deviated significantly from a single exponential decay 
indicating rebinding (Figure 33D), in agreement to what has been reported before [93]. The 
interaction of IFNβ with immobilized ifnar2-EC had been investigated only at increased ionic 
strength in order to overcome its otherwise strong non-specific binding to the surface [76]. At 
the PEG polymer brush surface used in this study, no significant non-specific binding of IFNβ 
was detectable at physiological ionic strength after fully blocking the chelator head groups 
with MBP-H10 (Figure 33B). Under these conditions, IFNβ bound substantially tighter to 
ifnar2-EC compared to IFNα2 (Figure 33B), while from the relative signals, a 1:1 
stoichiometry between ifnar2-EC and IFNβ was confirmed. The dissociation was very slow 
with an estimated kd value of 0.0005 s
-1. From the I47A mutant of ifnar2-EC, IFNβ dissociated 
with a rate constant of 0.005  ±  0.002  s
-1 (Figure 33C). From this value, the kd value of 
approximately 0.0005 s
-1 was confirmed for the wild-type complex, assuming the same 10-
fold difference as observed at high ionic strength [76]. Thus, the half-life of the complex with 
ifnar2-EC is probably about 20-fold higher for IFNβ compared to IFNα2. The observed 
association was strongly mass transport limited (Figure 33E) indicating that the association 
rate constant ka is well above 5·10
6 M
-1s
-1. The high ka can be explained by electrostatic rate 
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enhancement, as IFNβ is positively charged and ifnar2-EC is strongly negatively charged at 
physiological pH.  
The strong dependence of the complex stability on the ionic strength suggests that 
electrostatic forces also stabilize the interaction of IFNβ with ifnar2-EC. This effect, however, 
could also be due to rebinding on the surface, which is dependent on the ka, and thus also on 
the ionic strength. Therefore the contribution of rebinding by injecting ifnar2-tl at high 
concentration (10 µM) during the dissociation phase was investigated (Figure 33F, G). In 
both cases, a significantly faster dissociation was observed resulting in corrected dissociation 
rate constants of 0.012  ±  0.003  s
-1 for IFNα2 and ~0.001  s
-1 for IFNβ. No significant 
differences in binding parameters of ifnar2-EC attached via a C-terminal H10-tag compared 
to immobilization via antibodies were detected. Also rebinding effects were not demonstrated 
to influence binding parameters dramatically. Thus this immobilization mode could be applied 
for all following binding experiments. 
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Figure 33   Interaction of IFNα2 and IFNβ with ifnar2-EC tethered onto a PEG  polymer brush. 
A: Cartoon of the binding experiment. B: Binding curve for 50 nM IFNα2 (red) and 
50 nM  IFNβ (black) to ifnar2-EC in comparison to 50  nM IFNβ exposed to 
immobilized MBP (green). C: Dissociation of IFNα2 and IFNβ from immobilized 
ifnar2-EC I47A. D: Fit and residuals for association and dissociation of IFNα2 shown 
in B. E: Fit and residuals for association and dissociation of IFNβ shown in B. F, G: 
Dissociation of IFNα2 (F) and IFNβ (G) from immobilized ifnar2-EC in absence 
(black) and in presence (red) of 10 µM ifnar2-tl. 
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6.2.3  Interaction of IFNs with ifnar1-EC 
In order to characterize the interaction with IFNα2 and IFNβ, ifnar1-EC was 
immobilized on a PEG polymer brush through its C-terminal his-tag (Figure 34A) and IFN in 
varying concentrations was injected. Binding of IFNα2 to immobilized ifnar1-EC was only 
detectable at concentrations above 300  nM and rapid dissociation was observed (Figure 
34B). This interaction was entirely specific as confirmed by control experiments without 
ifnar1-EC on the surface (data not shown). From the equilibrium responses Req observed for 
IFNα2 at concentrations between 100 nM and 100 µM, titration curves were obtained. A KD 
value of 5 ± 2 µM was determined by fitting a Langmuir isotherm (Figure 34C). Hence, the 
affinity of IFNα2 towards ifnar1-EC is about three orders of magnitude lower than for ifnar2-
EC. The maximum binding signal Rmax obtained from such titration corresponded to a 1:1 
interaction between ifnar1-EC and IFNα2 assuming full activity of the immobilized ifnar1-EC. 
In addition IFNα2 S136C was characterized with respect to experiments with fluorescence 
labeled ligand. Here no differences to binding parameters determined for IFNα2 wild-type 
were observed (Table 4). The fast dissociation of IFNα2 (kd ~ 1 s
-1) was resolved by TIRFS 
detection in a recent publication [94]. 
Before measuring the binding of IFNβ to ifnar1-EC excessive binding sites on the 
surface were blocked by MBP-H10 (not shown). The interaction of IFNβ with immobilized 
ifnar1-EC was much more stable compared to the binding of IFNα2 (Figure 34D). 
Association and dissociation phases were well fitted by mono-exponential models (Figure 
34E). From the fitting, a ka value of (3 ± 2)·10
5 M
-1s
-1 and a kd value of 0.017 ± 0.004 s
-1 were 
obtained. The binding signals corresponded to a 1:1 stoichiometry between IFNβ and ifnar1-
EC.  
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Figure 34   Binding of IFNs to immobilized ifnar1-EC on a PEG polymer brush. A: Cartoon of the 
single interaction binding experiment. B: Binding of IFNα2 in various concentrations 
(100 nM, 300 nM, 1 µM, 3µM, 10 µM, 30µM and 100 µM) to immobilized ifnar1-EC. 
C: Equilibrium response of IFNα2 binding to ifnar1-EC vs. concentration and the 
fitted Langmuir isotherm. D: Binding of 50 nM IFNβ to immobilized ifnar1-EC. E: 
Monoexponential fit to the association and dissociation shown in D. 
  
In order to identify a possible cooperative effect of ifnar2-EC, binding experiments 
with a stoichiometric complex of IFNα2 with ifnar2-tl were carried out (Figure 35A). This 
complex with a life-time of ~100  s can be assumed static during the time-scale of the 
interaction with ifnar1-EC. Binding curves for 0.1 and 10  µM IFNα2-ifnar2-tl-complex are 
shown in Figure 35B. The relative binding signals obtained from a full titration (data not 
shown) confirmed a 1:1 stoichiometric ratio between the IFNα2-ifnar2-tl complex and 
immobilized ifnar1-EC. A KD value of 4  ±  2  µM was obtained, which was not significantly 
different from the KD determined for IFNα2 alone. This result suggests the interaction 
between IFN and ifnar1-EC is not stabilized by cooperative interactions.  
Similar to IFNα2, no significant differences in the binding rates were observed for 
ifnar2-tl-bound IFNβ compared to free IFNβ (Figure 35B, C). Also a 1:1 stoichiometric ratio 
was confirmed. For free as well as ifnar2-tl-bound IFNβ a KD value of 50  ±  30  nM was 
obtained. The interaction of the IFNβ-ifnar2-tl complex with ifnar1-EC was also investigated 
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in solution by a binding inhibition assay (Figure 36). The KD obtained from this experiment 
was 30 ± 10 nM, i.e. in good agreement with the KD determined for the interaction at the 
surface. 
In order to check if immobilized ifnar1-EC interacts with ifnar2-EC alone, several 
binding experiments were performed. Up to ifnar2-tl concentrations of 50 µM no binding 
signal could be observed, indicating a KD > 100 µM. Since binding activity of both proteins 
was checked before, a direct interaction between the two extracellular domains of ifnar in the 
detectable concentration range could be excluded. These results underline the observation, 
that no cooperative effect for the IFN binding to ifnar1-EC could be detected after the pre-
formation of an IFN-ifnar2-tl complex. 
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Figure 35   Interaction of immobilized ifnar1-EC with IFN-ifnar2-tl binary complex. A: Cartoon 
of the binding experiment. B: Binding of 100 nM IFNβ-ifnar2-tl (red), 100 nM IFNα2-
ifnar2-tl (green) and 10  µM IFNα2-ifnar2-tl (black) to immobilized ifnar1-EC in 
comparison (normalized to the amount of ifnar1-EC on the surface). C: Fit of single 
exponential models to the association and dissociation phase for the interaction of 
100 nM IFNβ-ifnar2-tl with ifnar1-EC as shown in E, and the residuals of the fit. 
 
Thus, the affinity of ifnar1-EC to IFNβ is two orders of magnitude higher than for 
IFNα2. Intriguingly, the association rate constant of IFNβ binding to ifnar1-EC is at least an 
order of magnitude lower compared to the binding to ifnar2-EC. The individual affinities were 
not influenced by the interaction with soluble ifnar2-tl indicating non-cooperative binding.  
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Figure  36  Binding inhibition assay with ifnar1-EC in solution. A: Binding of IFNβ-ifnar2-tl 
(20 nM) on immobilized ifnar1-EC with various ifnar1-EC concentrations in solution 
(300nM (red), 30nM (green), 0 nM (blue)). B: Initial slopes of the binding inhibition 
assay.    
 
Table 4   Rate and equilibrium constants of the interaction with ifnar1-EC IFNs and different 
mutants. Mean values and standard deviations were determined from at least three 
independent experiments. IFNα2 S136C was labeled with OG-488 or AF-488 at the 
additional cysteine. ka values were calculated from KD and kd.  
 Ifnar1-EC 
IFN  ka [M
-1s
-1]  kd [s
-1]
  KD [nM] 
IFNα2 wt  ~ 2 ·10
5 ~ 1  5000 ± 2000 
IFNα2 S136C  ~ 2 ·10
5 ~ 1  ~5000 
IFNα2 / ifnar2-tl   ~ 2.5 ·10
5 ~ 1  4000 ± 2000 
IFNα2 R149A  ~ 2 ·10
5 ~ 1  5000 ± 2000 
IFNβ   (3 ± 2)·10
5 0.017 ± 0.004  50 ± 30 
IFNβ
 / ifnar2-tl  (4 ± 2)·10
5 0.019 ± 0.004  50 ± 30 
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6.2.4  Interaction of ifnar1-EC sub-fragments with IFNα2 and IFNβ 
In order to identify the ligand binding epitopes for IFNα2 and IFNβ several ifnar1-EC 
sub-fragments were prepared. These fragments were termed H10-SD12, SD34-H10, H10-
SD123 and SD234-H10 (SD1234-H10 for ifnar1-EC). The influence of the N-terminal 
attachment (relevant for H10-SD12 and H10-SD123) on ligand binding was investigated with 
an N- and C-terminal attached construct termed SD1234-DT(Figure 37A). The reduced 
surface binding capacity observed for SD1234-DT compared to SD1234-H10, as well as 
imidazole-induced dissociation experiments (Figure 37B) confirmed that both histidine-tags 
were involved in tethering the protein to the surface. Interaction of IFNα2 and IFNβ with 
immobilized SD1234-DT is shown in Figure 37C, D. The KD of the interaction with IFNα2 was 
determined from the equilibrium response, while the rate constants of the interaction with 
IFNβ were determined by fitting exponential functions to association and dissociation phase 
of the binding curves (Figure 38C, D). Furthermore, the kd of the dissociation of IFNα2 
(Figure 38B) from immobilized SD1234-DT was determined by TIRFS (kd  ~1 s
-1). IFNα2 
S136C site-specifically labeled with the fluorescence dye Alexa Fluor 488 (
AF-488IFNα2) was 
used, which was shown to interact with ifnar2-EC and ifnar1-EC as wild-type IFNα2 (section 
6.2.1 and [99]). All dissociation and rate constants obtained for IFNα2 and IFNβ were in 
agreement to the values observed for ifnar1-EC (SD1234-H10). Thus the additional N-
terminal attachment of ifnar1-EC has no effect on ligand binding. 
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Figure  37    Ifnar1-EC immobilization with one C-terminal histidine-tag in comparison to the 
double-tagged construct SD1234-DT. A: Schematic of immobilization.  B: 
Dissociation of immobilized SD1234-H10 (red) and SD1234-DT (blue) by 20 mM 
imidazole. C, D: Binding of IFNα2 (C) and IFNβ (D) to SD1234-DT immobilized on a 
polymer brush surface as detected by RIfS (the bar marks the injection period). 
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Figure 38   Analysis of association and dissociation as shown in Figure 37 . A: Association of 
AF-488IFNα2 (200 nM) to SD1234-DT (blue) as detected by TIRFS in comparison to the 
same experiment carried out with SD1234-H10 (red). B: Dissociation of 
AF-488IFNα2 
from SD1234-DT (blue) and SD1234-H10 (red). C:  Association of IFNβ2 (100 nM) to 
SD1234-DT (blue) as detected by RIfS in comparison to the same experiment carried 
out with SD1234-H10 (red). D: Dissociation of IFNβ from SD1234-DT (blue) in 
comparison to SD1234-H10 (red).  
 
In the same manner, binding of IFNα2 and IFNβ was assessed for the sub-fragments. 
Up to concentrations of 10 µM IFNα2 and 200 nM IFNβ no specific binding was detectable 
for H10-SD12 and SD34-H10 as well as for SD234-H10 (Figure 39A-C). Thus, the KD´s of 
these sub-fragments were >100  µM for IFNα2 and >2  µM for IFNβ. In contrast 
uncompromised binding of both IFNs was observed for H10-SD123 (Figure 39A-C). The 
interaction constants determined from these curves were very similar to the values observed 
for SD1234-H10 (Table 5).  
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Figure  39    Binding of IFNα2 and IFNβ to the different sub-fragments immobilized on the 
transducer surface. A: Response during injection of 1 µM IFNα2 to SD1234-H10, 
H10-SD123, H10-SD234 H10-SD12, SD34-H10 in comparison (color coding as 
shown in the inset). Signals were normalized to the molar surface concentration of the 
immobilized protein. B: Response during injection of 50 nM IFNβ onto SD1234-H10, 
H10-SD123, SD234-H10, H10-SD12, SD34-H10 in comparison (same color coding as 
in A). C: Response during injection of 1 µM (·······) and 10 µM (——) IFNα2 onto 
H10-SD123 (red) and SD234-H10 (blue) in comparison.  
 
In order to restore ligand binding activity, H10-SD12 and SD34-H10 were co-
immobilized in stoichiometric amounts (Figure 40B) onto solid-supported, fluid lipid bilayers 
in order to allow simultaneous interaction with the ligand (Figure 40A). Still, neither for IFNα2 
(Figure 40C) nor for IFNβ (Figure 40D) significant binding was detectable, indicating that the 
linkage between H10-SD12 and SD34-H10 is required for the formation of an intact binding 
site.  
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Figure 40   Co-immobilization of H10-SD12 and SD34-H10 (II) on solid-supported lipid bilayers. 
A: Cartoon of the experiment. B: Sequential tethering of H10-SD12 (I) and SD34-H10 
(II) to the surface. C,D: Response during injection of 1 µM IFNα2 (C) and 50 nM 
IFNβ (D) onto H10-SD12 and SD34-H10 co-immobilized on solid-supported lipid 
bilayers in comparison to SD1234-H10. 
 
To confirm that loss of binding activity for H10-SD12, SD34-H10 and SD234-H10 was 
not due to denaturation of the protein during immobilization on the surface, another assay to 
assess binding was devised (Figure 41A). Ifnar2-EC was immobilized on the surface 
followed by binding of IFNβ which binds quasi-irreversibly to ifnar2-EC (Figure 41B). 
Subsequently, binding of SD1234-H10 and the sub-fragments to ifnar2-EC-bound IFNβ was 
studied (Figure 41B). In Figure 41C binding of the sub-fragments is compared with that of 
SD1234-H10. Again, specific binding was only detectable for the sub-fragment H10-SD123. 
All these experiments confirmed that the N-terminal Ig-like domains 1, 2 and 3 on a single 
polypeptide chain were required for the formation of an intact binding site for IFNα2 and 
IFNβ.  
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Figure 41   Binding of ifnar1-EC species to the complex of immobilized ifnar2-EC and IFNβ. A: 
Schematic of the sandwich assay: after immobilization of ifnar2-EC excess chelators 
are blocked with MBP-H10 (not shown); then, IFNβ binds irreversibly to ifnar2-EC, 
followed by exposure to the respective ifnar1-EC variant. B: Typical binding of IFNβ 
(I) to immobilized ifnar2-EC, followed by an injection of 50 nM H10-SD12 (II) and of 
50 nM SD1234-H10 (III). C: Binding curves for SD1234-H10 and the sub-fragments 
in comparison (50 nM each, the color coding is shown in the inset). 
 
Table 5    Affinities and rate constants of the interaction with IFNα2 and IFNβ determined for 
ifnar1-EC (SD1234-H10), SD1234-DT and H10-SD123. 
Ifnar1 IFNα2 IFNβ 
Fragment  kd KD [µM]  ka [M
-1s
-1]  kd [s
-1]
  KD [nM] 
SD1234-H10  1.0 ± 0.3  ~5  (5 ± 2)·10
5 0.017 ± 0.005  50 ± 20 
SD1234-DT  1.0 ± 0.2  ~6  (5 ± 2)·10
5 0.017 ± 0.005  50 ± 20 
H10-SD123  1.3 ± 0.2  ~8  (5 ± 2)·10
5 0.019 ± 0.006  70 ± 20 
 
6.2.5 IFNα2 and IFNβ compete for the same binding site on ifnar1-EC 
Since the analysis of different sub-fragments did not indicate different binding 
domains in ifnar1-EC for both IFNα2 and IFNβ, it was investigated whether these two IFNs 
actually bind competitively to an overlapping epitope. In order to discriminate these two IFNs 
AF-488IFNα2 was used. Binding was monitored in real-time by simultaneous TIRFS-RIf 
detection [100]. Both the fluorescence and the mass-sensitive signal monitored in real-time 
during a typical experiment are shown in Figure 42. After immobilization of ifnar1-EC, first 
1 µM 
AF-488IFNα2 was injected (Figure 42A (I)), followed by an injection of 1 µM 
AF-488IFNα2 
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mixed with 100  nM unlabeled IFNβ (Figure 42A (II)), then only 100  nM IFNβ was 
injected(Figure 42A (III)). The fluorescence signals during the first two injections were 
compared (Figure 42B). Fast, transient binding of IFNα2 was detectable in the fluorescence 
channel with a similar characteristic as observed for unlabeled IFNα2 (Figure 34B). The 
sensitivity of RIf-detection is too low to detect binding at this IFNα2 concentration, because a 
rather low surface concentration of SD1234-H10 was used for these measurements. When 
IFNα2 mixed with IFNβ was injected, a decay of the fluorescence signal after the initial, fast 
rise was observed (Figure 42C). This decay can be ascribed to labeled IFNα2 being 
exchanged for unlabeled IFNβ, which binds more stably to ifnar1-EC. Binding of IFNα2 is 
much faster, because of its higher concentration, while the association rate constants are 
very similar. Binding of IFNβ with its typical association and dissociation characteristics was 
simultaneously detected on the RIf-channel (Figure 42B (III)). For the IFNβ injection without 
IFNα2 a very similar binding curve was detected for IFNβ on the RIf-channel while no signal 
was detectable on the fluorescence channel. More detailed analysis of the binding curves at 
different concentrations confirmed that the rate constants of the interaction did not change, 
corroborating competitive binding of IFNα2 and IFNβ to ifnar1-EC.  
The same experiment was carried out with H10-SD123 immobilized on the surface. A 
comparison of the curves for 1 µM IFNα2 in the presence and absence of 100 nM IFNβ is 
shown in Figure 42D. Very similar shapes of the curves as for ifnar1-EC were obtained, 
confirming that IFNα2 and IFNβ bind to an overlapping epitope formed by the three N-
terminal Ig-like domains of ifnar1-EC. 
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Figure 42   Competition of IFNα2 and IFNβ for the ifnar1-EC binding site. A: Cartoon of the 
competition experiment. B: Interference signal (black) and fluorescence signal (red) 
during injection of 
AF-488IFNα2 (1µM) alone (I), mixed with IFNβ (II) and injection of 
IFNβ alone (III) on immobilized ifnar1-EC. C: Overlay of the fluorescence signals of 
injections I (black) and II (red). D: Overlay of the fluorescence signals of injections I 
(black) and II (red) for the same experiment carried out with immobilized H10-SD123. 
6.2.6  Identification of residues critical for interferon binding 
 In order to identify individual residues involved in interferon binding, several amino 
acids on every sub-domain were mutated. Most mutants were expressed in equal amounts 
like the wild-type protein. The major part of the mutants was also properly folded except 
W250A as checked by analytical SEC after one freeze and thaw cycle (data not shown). 
Since interaction studies with wild-type IFNα2 require high amounts of protein (Figure 43A), 
the high affinity IFNα2 mutant IFNα2-HEQ as well as IFNβ were used for the identification of 
relevant mutations. For IFNα2-HEQ a K D value of 70 nM ± 20 nM and dissociation rate 
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constant of ~ 0.025 s
-1 was determined (Figure 43C), which is comparable to IFNβ. The 
binding parameters for ifnar1-EC mutants were quantified by RIfS (Figure 43C; D). The 
results of all titration experiments performed to estimate the KD are summarized in Table 6.  
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Figure  43  Interactions of IFNα2, IFNβ and IFNα2-HEQ with different ifnar1-EC mutants 
immobilized on an NTA-surface. A: Binding curve of IFNα2 (1, 3 and 10µM) on ifnar-
EC wild-type (red) and W129A (blue). B: The same experiment with 50 nM IFNβ. C: 
Binding of IFNα2-HEQ to ifnar1-EC in different concentrations (light blue: 30 nM, 
red: 50 nM, yellow: 100 nM, green: 300 nM). D: Binding of IFNβ (100 nM) to 
different immobilized ifnar1-EC mutants (red: wild-type, green: K251A, light blue: 
N155T, magenta: E111A, grey: F136A, blue: Y70A). 
Residues on SD1 (Y70A) and mainly SD2 (E111A, K113, W129A and F136A) were 
identified to decrease affinity at least by a factor of 10 for IFNβ as well as for IFNα2-HEQ 
(Figure 44). Interestingly N155T increased affinity for IFNβ while it reduced affinity for IFNα2-
HEQ. However, these results were in good agreement with results obtained from 
mutagenesis studies on bovine ifnar1-EC [84]. Also on SD3 one residue (K251A) was 
identified to be involved in binding, but the effect was only minute and only detectable for 
IFNα2-HEQ. Since SD4 was not expected to be involved in ligand binding, only two mutants 
were generated on this sub-domain (D298A, N368D). These mutants did not reduce affinity 
compared to wild-type ifnar1-EC. 
Site directed mutagenesis study confirmed that IFNα2 and IFNβ use mainly the same 
residues on ifnar1 for binding. It is possible, that individual residues accentuate either IFNα2 
 72   Results 
or IFNβ. But it was concluded, that the same hot spots of binding are involved in the 
recognition of both IFNs. Thus in case of IFNα2 and IFNβ differential signaling seemed not to 
be encoded by structural differences in the ligand recognition process. 
Table  6    Dissociation constants determined for different ifnar1-EC mutants determined by 
titrating IFNα2-HEQ and IFNβ to immobilized receptor.    
Mutant  KD (IFNα2-HEQ)  KD (IFNβ)  Remark 
           
Y70A  > 3µM  > 500nM    
R76A  like wild-type  like wild-type   
E111A  340+/-150 nM  > 2µM   
K113A  > 3µM  > 2µM  difficult immobilization 
W129A  > 3µM  > 2µM   
F136A  > 3µM  > 2µM   
N155T  200+/-40 M  1+/-0.3 nM  increased affinity for IFNβ kd=0.0006 
L247A  like wild-type  like wild-type   
W250A  -  -  protein aggregation  
K251A  130+/-20 nM  like wild-type   
D298A  like wild-type  like wild-type   
N368D  like wild-type  like wild-type   
wild-type  70+/-20 nM  50+/-20 nM    
 
B A
SD1
SD2
Y70
W129
F136 N155
E111
K113
 
Figure 44  A, B: Model of ifnar1-EC SD1 and SD2. The structure is based on the NMR-structure 
of ifnar2-EC. Residues which decrease affinity toward IFNα2 and IFNβ  are depicted 
in red, N155 is depicted in blue.  
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6.3  Complex formation on lipid bilayers 
6.3.1 Introduction 
In order to investigate stoichiometry and dynamics of ternary complex formation an 
experimental set-up to simulate the binding processes at the extracellular domains of ifnar 
was required (Figure 43). The lateral mobility of the plasma membrane was mimicked by a 
lipid bilayer fused to a glass substrate, which was termed fluid support (Figure 43A). The 
proper formation and thickness of the bilayer was monitored by RIfS before conditioning 
(imidazole, EDTA, Ni
2+). In the next step proteins were sequentially immobilized via their 
histidine-tags on a chelatorlipid mimicking the anchoring by the trans-membrane domain 
(Figure 43B, C). In combination with RIf it was possible to control the absolute and relative 
surface concentrations of ifnar1-EC and ifnar2-EC. After co-immobilization the complex 
assembly was induced by IFN-injection (Figure 43D, E). Lateral mobility of the receptor was 
expected to mediate proper spatial arrangement of the receptor components, but a solid 
support is expected to reduce porotein mobility (Figure 43F). All experiments probing 
complex formation and stoichiometry were organized in this sequence. 
 ifnar2-EC
attachment
    ifnar1-EC
   attachment
bilayer fusion and
   pre-treatment
A BC
X
IFN injection
DE
complex assembly non-fluid support
F
 
Figure  45    Schematic of a co-immobilization experiment for probing complex assembly. A 
unilaminar vesicle fuses to the surface and form a fluid lipid bilayer (I). After per-
treatment ifnar2-EC and ifnar1-EC are sequentially immobilized (II+III). Then IFN is 
injected (IV) initializing complex formation (V). On a non-fluid support by using a 
PEG polymer brush proper complex formation is not expected (VI).   
6.3.2  Interaction of ifnar1-EC and ifnar2-EC on fluid support 
Before co-immobilization of ifnar1-EC and ifnar2-EC any effect of the bilayer on IFN 
binding had to be excluded by individual interaction experiments on fluid support. When 
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ifnar1-EC or ifnar2-EC were individually immobilized on solid-supported lipid bilayers (Figure 
46A), the binding curves obtained for IFNα2 and IFNβ binding to ifnar2-EC (Figure 46B, C) 
and ifnar1-EC (Figure 46D, E), respectively, were very similar to the corresponding 
measurements on the non-fluid polymer brush support. The rate and equilibrium constants 
obtained from these curves matched the rate constants determined from the measurements 
on non-fluid support. Neither for IFNα2 nor for IFNβ significant non-specific binding was 
detectable on the solid-supported lipid bilayers (Figure 46B, D, E). 
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Figure 46  Ligand binding to ifnar1-EC and ifnar2-EC tethered on solid-supported lipid bilayers 
as detected by RIfS. A: Cartoon of an experiment probing individual interactions. The 
unilaminar vesicle fuses to the glass support (I) and subsequently the receptor 
attached to the surface (II) followed by IFN-injection. B: Interaction of 50 nM IFNα2 
(red) and 50 nM IFNβ (black) with ifnar2-EC in comparison to 50 nM IFNβ exposed 
to a surface loaded with MBP-H10 (green). C: Fit of the association and dissociation 
curves shown in B. D: Interaction of 10 µM IFNα2 (black) with immobilized ifnar1-
EC in comparison to 10  µM IFNα2 exposed to a surface loaded with MBP-H10 
(green). E: Interaction of 100  nM IFNβ (black) with ifnar1-EC in comparison to 
100 nM IFNβ exposed to a surface loaded with MBP-H10 (green). 
For the investigation of complex assembly ifnar1-EC and ifnar2-EC were sequentially 
tethered to the surface. Upon co-immobilization binding kinetics of IFNα2 drastically changed 
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(Figure 47A, B). No significant dissociation was observed within 15  min, and a second 
injection of IFNα2 did not give any significant signal (data not shown). No dissociation of 
IFNα2 was discernible only if 1:1 molar ratio for ifnar1-EC and ifnar2-EC was strictly 
maintained. With a molar excess of ifnar1-EC, partial fast dissociation of IFNα2 was 
observed, and the amount of stably bound ligand corresponded to the amount of tethered 
ifnar2-EC (Figure 47C). With a molar excess of ifnar2-EC, a partial dissociation with a rate 
constant corresponding to the ifnar2-IFNα2 interaction was observed, and the amount of 
stably bound ligand corresponded to the amount of ifnar1-EC on the bilayer (Figure 47D).  
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Figure 47  Ligand binding to ifnar1-EC and ifnar2-EC co-immobilized on solid-supported, fluid 
lipid bilayers. A: Immobilization of ifnar2-EC (I) and ifnar1-EC (II) in stoichiometric 
ratio, and interaction with 100 nM IFNα2 (III). B: Enlargement of IFNα2 binding and 
dissociation as shown in A. C, D: Interaction with 100 nM IFNα2 with an excess of 
ifnar1-EC (C) and ifnar2-EC (D). Interaction of IFNα2 (1 µM) with deglycosylated 
ifnar1-EC co-immobilized with ifnar2-EC on lipid bilayer. 
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The same results were also obtained for deglycosylated ifnar1-EC (Figure 47E) which 
demonstrates, that glycosylation has no effect on complex formation. All results confirmed 
that with IFNα2 a complex with a stoichiometry of 1:1:1 was formed, termed the ternary 
complex. 
Formation of a stable stoichiometric ternary complex was only observed on fluid 
supports (Figure 48), confirming that orientation and lateral reorganization of the receptor 
domains were required to obtain maximum binding affinity. This observation was underlined 
by FRAP experiments. For 
OG-488ifnar2-EC tethered to the chelator lipid, a diffusion constant 
of 1  ±  0.5  µm²/s was determined, which is very similar to the diffusion constant of GPI-
anchored proteins in living cells [101]. No significant change in recovery time was observed 
upon co-immobilization with ifnar1-EC, while binding of IFNα2 clearly reduced the recovery 
rate by a factor of 2 (Figure 49). These results also confirmed that no substantial interaction 
between ifnar1-EC and ifnar2-EC takes place in the absence of the ligand. 
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Figure  48  Fluid and non-fluid support in ternary complex assembling. A: Cartoon of the 
experiment. B: Dissociation of IFNα2 from the ternary complex with ifnar1-EC and 
ifnar2-EC on lipid bilayers (black) and on polymer brush support (blue), compared to 
the dissociation from ifnar2-EC alone (red).  
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Figure 49  FRAP experiment carried out with ifnar2-EC S35C labeled with OG488 tethered to 
chelator lipids in a solid-supported lipid bilayer. Recovery curves of ifnar2-EC OG-
488 in presence of ifnar1-EC before (blue) and after (red) addition of 100 nM IFNα2. 
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Since for the wild-type proteins no dissociation from the ternary complex was 
observed, several mutants of ifnar2-EC and IFNα2 forming relatively less stable binary 
complexes with each other compared to their wild-type counterparts were investigated 
(Figure 50A, B). IFNα2 dissociated from ifnar2-EC I47A with a rate constant of 0.2 s
-1 (20-
fold higher than wild-type ifnar2-EC). Upon co-immobilization of ifnar-1EC, a kd of 
0.001 ± 0.0002 s
-1 was observed (Figure 50C). For IFNα2 R149A (KD: 500 nM, kd ~ 2 s
-1), a 
dissociation rate constant of 0.01 ±0.003 s
-1 in presence of tethered ifnar1-EC was observed 
(Figure 50D). 
From these experiments it was estimated, that in presence of ifnar1-EC the apparent 
affinity is approximately 200-fold higher compared to the affinity towards ifnar2-EC alone. 
This was mediated by the formation of a ternary complex at high receptor surface 
concentration. 
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Figure 50  A, B: Dissociation of IFNα2 from both ifnar1-EC and ifnar2-EC on lipid bilayers 
(blue) compared to ifnar2-EC alone (red) observed for ifnar2-EC I47A with wild-type 
IFNα2 (A) and for wild-type ifnar2-EC with IFNα2 R149A (B). C, D: Fit of a mono-
exponential decay to the dissociation from the ternary complex shown in A (C) and B 
(D), and the residuals. 
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Table  7  Rate and equilibrium constants of the interaction with ifnar1-EC and ifnar2-EC 
determined for different IFNs and different mutants (n.b., no binding detectable). 
Mean values and standard deviations were determined from at least three independent 
experiments.  
 Ifnar2-EC  Ifnar2-EC/Ifnar1-EC (co-immobilized on lipid 
BL at high surface concentrations) 
IFN  ka [M
-1s
-1]  kd [s
-1]
  KD [nM]  ka [M
-1s
-1]  kd [s
-1]
  KD [nM] 
IFNα2 wt  (3 ± 1)·10
6 0.012 ± 0.002  3 ± 1  (3 ± 1)·10
6 ~0.0001 ~0.03 
IFNα2 S136C  (3 ± 1)·10
6 0.013 ± 0.002  3 ± 1  (3 ± 1)·10
6 ~0.0001 ~0.03 
IFNα2 wt on 
ifnar2-EC I47A
 
(3 ± 1)·10
6 0.20 ± 0.04  60 ± 20  -  0.0012±0.0002  - 
IFNα2 R149A  -  ~ 2  500 ± 100  -  0.010±0.003  - 
IFNβ   > 5·10
6 ~ 0.001  < 0.1  -  < 0.0005  - 
IFNβ on 
ifnar2-EC I47A 
> 5·10
6 0.003 ± 0.001  < 0.6  -  -  - 
IFNβ with 500mM 
NaCl 
> 5·10
6 0.005 ± 0.002  < 1  -  < 0.0005  - 
 
6.3.3  Complex stability depends on receptor surface concentration  
All measurements demonstrating a stable ternary complex, however, were carried out 
at very high receptor surface concentrations (approximately 20-40 fmol/mm², i.e. 20-40% of a 
monolayer). Thus, simultaneous RIfS/TIRFS detection was carried out to monitor association 
and dissociation processes under controlled surface conditions at low receptor surface 
concentrations. Binding of labeled IFNα2 to the receptor on lipid bilayers was measured at 
different absolute surface concentrations of the receptor in a stoichiometric ratio of ifnar1-EC 
and ifnar2-EC (Figure 51). At high surface concentration of ifnar1-EC and ifnar2-EC, 
fluorescence detection principally showed similar dissociation phases like RIfS (Figure 51A). 
However, a decay of the signal while rinsing was observed. This was not due to ligand 
dissociation, as stable binding was confirmed by simultaneous RIfS detection (data not 
shown), but can be ascribed to photobleaching. With decreasing surface concentrations of 
ifnar1-EC and ifnar2-EC a decreasing stability of the ternary complex was observed (Figure 
51B). The dissociation curves were fitted by a single exponential decay (Figure 51B, C), and 
increasing kd values were obtained with decreasing surface concentrations. In Figure 51D, 
the dissociation rate constants were plotted as a function of receptor surface concentration, 
the corresponding values are listed in Table 8. At the lowest receptor surface concentration 
of approximately 0.3 fmole/mm² (~200 molecules/µm²), the stability of the ternary complex 
was only 3-times higher than for ifnar2-EC alone. For surface concentrations of 2-
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4 fmole/mm² kd values corresponding to the affinities which have been observed in binding 
assays with living cells were determined [102]. 
Table 8  Rate and equilibrium constants of IFNα2 binding at different stoichiometric surface 
concentrations of ifnar1-EC and ifnar2-EC on supported lipid bilayers. KD was 
calculated using the average ka of (3 ± 1)·10
6 M
-1s
-1
Ifnar1-EC 
[fmol/mm²] 
ka [10
6M
-1s
-1]  kd [10
-3s
-1]
  KD [nM] 
12 ± 3  1 ± 0.3  0.5 ± 0.1  0.17 ± 0.06 
8 ± 2  1 ± 0.3  0.5 ± 0.1  0.17 ± 0.06 
5.5 ± 1  3 ± 1  0.6 ± 0.1  0.21 ± 0.07 
4 ± 1  4 ± 1  0.8 ± 0.2  0.28 ± 0.1 
2 ± 0.4  5 ± 2  1.4 ± 0.2  0.46 ± 0.16 
1 ± 0.2  3.5 ± 1  2.1 ± 0.2  0.70 ± 0.24 
0.5 ± 0.1  3 ± 1  3.3 ± 0.3  1.11 ± 0.4 
0.3 ± 0.1  4 ± 1  4.4 ± 0.4  1.48 ± 0.5 
0  4 ± 1  12 ± 1  4 ± 1.5 
 
The association phases of the binding curves normalized to the saturation signal are 
shown in Figure 51E. At receptor surface concentrations below 8 fmol/mm², the association 
curves overlayed. These curves were fitted well by a pseudo first-order model (Figure 51F) 
and gave association rate constants very similar to the interaction of IFNα2 with ifnar2-EC 
alone (Table 8). At higher surface concentration, significantly lower association rate 
constants were obtained and systematic deviations from the model, as well as from the other 
binding curves were observed (Figure 51F). This was probably due to mass transport 
limitations at these high receptor surface concentrations, which have already been observed 
for the interaction of IFNα2 with ifnar2-EC alone. 
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Figure 51  IFNα2 interaction with ifnar1-EC and ifnar2-EC tethered onto supported lipid 
bilayers as detected by TIRFS. A: binding of 100  nM AF-488-labeled IFNα2 at 
different surface concentrations of ifnar2-EC and ifnar1-EC in a stoichiometric ratio 
(black: 12 fmol/mm²; red 8 fmol/mm²; green: 4 fmol/mm²; blue: 2 fmol/mm²; brown: 
1  fmol/mm², orange: 0.5  fmol/mm²). B: dissociation phases of the binding curves 
shown in A normalized to the signal at the beginning of dissociation (same color 
coding as A) including the fit curve of a mono-exponential decay (black lines). C: 
residuals for fitting curves shown in B (same color coding as A). D: dissociation rate 
constant as a function of the surface concentration of the receptor. E: association 
phases of binding curves shown in A normalized to the saturation signal (same color 
coding as A). F: residuals of a first-order association model fitted to the curves shown 
in E. 
6.3.4  Dynamic exchange processes on the ternary complex  
The dependence of the complex stability on the receptor surface concentration 
suggested that the ternary complex is not static, but stabilized by fast re-association, i.e. the 
kinetics which depends on the receptor surface concentration. This was further corroborated 
by the observation that stable ternary complexes were formed at low surface concentrations 
of ifnar2-EC but high surface concentrations of ifnar1-EC (data not shown). In order to 
analyze this kinetic stabilization, the apparently stable ternary complex formed with 
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fluorescence labeled IFNα2 was challenged by injecting unlabeled IFNα2 or ifnar2-tl (Figure 
52A). Already at a concentration of 1 µM unlabeled IFNα2 an exchange rate of 0.002 s
-1 was 
observed. At the same time the total amount of bound IFN did not change as simultaneously 
detected by RIfS (data not shown). In contrast no significant change in dissociation kinetics 
was observed when ifnar2-tl was injected, even at a concentration as high as 10 µM (Figure 
52A). 
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Figure 52  Chase experiments with fluorescent labeled IFNα2 bound to ifnar2-EC and ifnar1-EC 
co-immobilized on supported lipid bilayers A: Dissociation of OG-488-labeled IFNα2 
(black) at high surface concentrations of both ifnar2-EC and ifnar1-EC, in the 
presence of 1 µM (green) and 10 µM (blue) ifnar2-tl, and in the presence of 1 µM 
unlabeled IFN (red). B: Dissociation of OG-488-labeled IFNα2 from the ternary 
complex at low surface concentration of ifnar2-EC in absence (black) and in presence 
(red) of 1 µM unlabeled IFNα2. 
Furthermore, even at much lower surface concentrations of ifnar2-EC 
(~0.5 fmol/mm²), fast exchange was observed in presence of 1 µM unlabeled IFNα2 (Figure 
52B). These experiments confirmed that the ligand does not dissociate from the surface and 
re-associates (rebinding-effect), because then ifnar2-tl should interfere as efficient as IFNα2 
does, and the effect should be much less pronounced at low surface concentrations. The fact 
that the ligand is much faster exchanged than the apparent dissociation rate furthermore 
corroborates the kinetic stabilization of the ternary complex.  
Binding assays with ifnar1 and ifnar2 co-immobilized on lipid bilayers were also 
carried out with IFNβ. However, very stable binding was observed already for the interaction 
with ifnar2-EC alone, and thus no substantial difference in stability could be observed in 
presence of ifnar1-EC. Upon challenging the ternary complex formed with IFNβ by injecting 
fluorescently labeled IFNα2, no exchange could be observed (data not shown), confirming 
the anticipated high stability of the ternary complex. Since the already formulated IFNβ could 
not be labeled appropriately, binding assays at low surface concentration were also not 
feasible.  
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6.3.5  Complex formation of ifnar1-EC sub-fragments on lipid bilayers 
The direct interaction assays revealed that the binding affinity towards IFNα2 and 
IFNβ decreased by more than a factor of >20 in case H10-SD12, SD34-H10 and SD234-
H10, while nearly full binding affinity was maintained for H10-SD123. Owing to the already 
low affinity of IFNs towards ifnar1-EC, the residual binding affinity could not be established 
by these assays. Furthermore the effects of sub-domain deletion on ternary complex 
formation remained unclear. Therefore ligand binding to ifnar2-EC co-immobilized with 
ifnar1-EC or its sub-fragments onto a solid-supported fluid lipid bilayer was investigated. It 
was shown before that with stoichiometric amounts of ifnar2-EC and ifnar1-EC (SD1234-
H10) at high surface concentrations (~25-50  fmol/mm²) IFNα2 binds at least 100-times 
stronger than to ifnar2-EC alone. Thus this binding assay was even more sensitive to low 
affinities, since the ligand is captured by the high-affinity interaction with ifnar2-EC, and 
subtle lateral interaction on the surface would be reflected by a decrease in the dissociation 
rate constant. 
For the sub-domains H10-SD12, SD34-H10 (data not shown) and SD234-H10 (Figure 
53E) no significant difference in the dissociation kinetics was observed compared to the 
dissociation from ifnar2-EC alone. Also upon co-immobilization of H10-SD12 and SD34-H10 
with ifnar2-EC, no change in the dissociation kinetics was observed (Figure 53A-C). From 
these assays, a loss of affinity by more than 2 orders of magnitude can be concluded for the 
sub-fragments H10-SD12, SD34-H10 and SD234-H10. In contrast a strong decrease in the 
apparent kd was observed for SD123 co-immobilized with ifnar2-EC (Figure 53D), almost as 
strong as for ifnar1-EC or SD1234-DT (Figure 53E). A kd of 0.0002 s
-1 was estimated by an 
exponential fit, i.e. two orders of magnitude slower than the dissociation from ifnar2-EC 
alone. The stability of the ternary complex formed upon co-immobilization with ifnar2-EC was 
compared in more detail for the variants ifnar1-H10, SD1234-DT and H10-SD123 applying 
the IFNα2 mutant L30A, which binds ~500-times weaker to ifnar2-EC (kd ~5 s
-1). The curve 
observed for SD1234-DT (data not shown) was indistinguishable from the curve obtained for 
SD1234-H10) with a kd of 0.015 s
-1. In case of H10-SD123, slightly faster dissociation was 
observed (kd: 0.025 s
-1) (Figure 53F). Thus, only small differences in ternary complex stability 
were observed for H10-SD123 compared to SD1234-H10 and SD1234-DT at these high 
receptor surface concentrations, confirming that ternary complex formation was possible 
without SD4. 
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Figure 53   IFNα2 binding to ifnar2 co-immobilized with different ifnar1-EC sub-fragments onto 
solid-supported lipid bilayers. A, B: Cartoon (A) and binding (B) of 100 nM IFNα2 
(IV) to co-immobilized ifnar2 (I), H10-SD12 (II) and SD34-H10 (III) (blue) compared 
to ifnar2 alone. C: Enlargement of IFNα2 binding and dissociation as shown in B. D: 
Dissociation from SD1234-H10 (red), H10-SD123 (green) co-immobilized with 
ifnar2-EC and ifnar2 alone (blue). E: The same as shown in D with SD234-H10 
(green) and SD1234-DT (black). F: Dissociation of IFNα2-L30A from SD1234-H10 
(black) and H10-SD123 (blue) co-immobilized with ifnar2-EC. The dotted lines are 
the mono-exponential fits of these curves. 
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Table  9    Dissociation rate constants of the interaction with IFNα2 and IFNα2 L30A 
determined for different ifnar1-EC constructs on fluid lipid bilayers at high surface 
concentrations (20-40 fmol/mm²). 
Ifnar1 IFNα2/ifnar2-EC IFNα2 L30A/ifnar2-EC 
Fragment  kd[s
-1]  kd[s
-1] 
SD1234-H10  ~0.0001   0.015 ± 0.003 
SD1234-DT  ~0.0001  0.017 ± 0.003 
H10-SD123  ~0.0002   0.025 ± 0.003 
6.3.6  Understanding of the role of SD4 in ternary complex assembling 
In order to study the effect of sub-domain deletion on ternary complex formation in 
vivo, ligand binding was analyzed in HEK293T cells overexpressing ifnar2 with different 
constructs of ifnar1-EC fused to the ifnar1 transmembrane and cytoplasmic domains. This 
work was done in collaboration with Gilles Uzé and José Van der Heyden (CNRS, 
Montpellier). Binding of IFNα2 and ifnar1 surface expression were quantified by FACS and 
the results are summarized in Figure 54. As expected for SD234 no increase in ligand 
binding was detectable. Interestingly for SD123 as well as for constructs with substituted 
SD4 (SD123-LRD2 and SD123-IL10R2D2) no high affinity ligand binding was observed 
(Figure 54B). Interestingly SD123-IL10V1V2, carrying two sets of amino acid sequences 
identical to ifnar1-SD4, was comparable to wild-type ifnar1. These results indicated that SD4 
has an important function for the assembling of the ternary complex in vivo.  
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Figure 54  A, B: Cell surface binding of IFNα2 on HEK293T cells over-expressing ifnar2 and 
different amounts of ifnar1. HEK293T cells were co-transfected with plasmids 
encoding EGFP, ifnar2 and ifnar1. The EGFP positive population was analyzed in 
FACS for the cell surface expression level of ifnar1 and ifnar2 (A) and for specific 
binding of 
AF-488IFNα2 (B). The binding of 
AF-488IFNα2 is expressed relative to the 
binding level measured on cells transfected with EGFP and ifnar2 alone (open 
circles). 
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For a better understanding of the role of SD4, ternary complex assembling was 
studied with several ifnar1-EC fragments and variants in more detail in vitro. SD123-LRD2 
with a C-terminal H10-tag (SD123-LRD2-H10), as well as SD1234 with an N-terminal H10-
tag (H10-SD1234) and SD123 with a C-terminal H10-tag (SD123-H10) were expressed in 
Sf9 insect cells and purified to homogeneity (section 6.1.1). As expected from the previous 
analysis, direct binding of IFNα2 and IFNβ was unaltered compared to SD1234-H10 for all 
these proteins (data not shown). Ternary complex assembling was studied by TIRFS-RIf 
detection with 
AF-488IFNα2 at ~3  fmol/mm² receptor surface concentration. This surface 
concentration is a good representation of the cell surface receptor density and more than one 
order of magnitude lower than the receptor surface concentrations used in the ternary 
complex formation assays described above.  
A comparison of ligand dissociation curves for different fragments is shown in Figure 
55B. For SD1234-H10, significantly faster ligand dissociation was observed compared to 
high receptor surface concentration, as expected for less efficient kinetic stabilization at 
these lower receptor surface concentrations. Under the same conditions, substantially faster 
dissociation was observed for SD123-LRD2-H10 than for SD1234-H10, in agreement with 
the low affinity observed for this variant on the cell surface. The dissociation kinetics, 
however, was still 4-5-times slower than from ifnar2-EC alone, indicating that the ternary 
complex still assembled, yet with a much lower efficiency.  
In order to test the role of orientation on surface affinity, ligand dissociation from 
ternary complexes formed with H10-SD1234, SD123-H10 and H10-SD123 under the same 
conditions (i.e. receptor surface concentrations) was investigated. Strikingly, also for H10-
SD1234, substantially faster ligand dissociation from the ternary complex was observed than 
for SD1234-H10. For both H10-SD123 and SD123-H10 ligand dissociation from the ternary 
complex was similarly fast as observed for SD123-LRD2-H10. However, by increasing the 
receptor surface concentration, the decrease in ligand binding affinity could be compensated 
(Figure 55C), suggesting less efficient recruitment of these ifnar1 constructs on the lipid 
bilayer. Tethering ifnar1-EC through both N- and C-terminus onto the membrane (SD1234-
DT) only had a minor effect on ligand dissociation (Figure 55D). Interestingly, it was 
observed, that the construct SD123-IL10V1V2 was comparable to wild-type ifnar1-EC in 
terms of complex stability (Figure 56). Probably the back-mutated regions in this domain 
were responsible for mediating the contribution of ifnar1-EC SD4 in complex assembly. 
Taken together, these results indicate that SD4 and its anchoring to the lipid bilayer 
plays a key role for the efficiency of ifnar1 recruitment into the ternary complex without being 
responsible for ligand recognition. 
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Figure 55   Comparison of different constructs to investigate the role of SD4 in complex assembly. 
A: Schematic of the constructs SD123-LRD2-H10, H10-SD1234 and H10-SD123 and 
their attachment to the lipid bilayer. B: Dissociation of IFNα2 from ifnar2-EC co-
immobilized with different constructs of ifnar1-EC on lipid bilayers (receptor surface 
concentration ~3  fmol/mm²). C: Dissociation of IFNα2 from ifnar2-EC co-
immobilized with H10-SD123 (red) and SD123-LRD2-H10 (blue) at different surface 
concentrations (solid line: ~7 fmol/mm²; dotted line: ~3 fmol/mm²). D: Dissociation of 
IFNα2 from ifnar2-EC co-immobilized with SD1234-H10 (blue), H10-SD1234 (red), 
and SD1234-DT (black) on supported lipid bilayers (receptor surface concentration 
~4 fmol/mm²). 
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Figure  56  A: Cartoon of SD123-V1V2 and SD123-IL-10-R2D2. B: Interaction of 100 nM 
AF-488IFNa2-S136C with ifnar1-EC (black) or SD123-IL10V1V2 (red) co-immobilized 
with ifnar2-EC. 
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6.3.7   Single particle analysis 
In order to get an intial view on the structure of the ternary complex, single particle 
analysis was applied. This work was done in collaboration with Gideon Schreiber, Weizmann 
Institute of Science. In the structural model (Figure 57) all results of the previous chapters 
were underlined. IFNα2 mediates the cross-linking of ifnar1-EC and ifnar2-EC via direct 
ligand-receptor interactions. As expected, no contact between the two receptor subunits was 
observed and SD4 was confirmed not to be involved in ligand binding. 
65.5 65.5
IFNα2
ifnar2-EC
ifnar1-EC
 
Figure 57   Structure of the ternary complex calculated from single particle analysis. 
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7 Discussion 
This work investigated the ligand induced assembly of the type I interferon receptor in 
order to understand the molecular basis of differential signaling by different interferons. An 
efficient expression and purification system to produce active and functional ifnar1-EC was 
established for in vitro binding assays. With quantitative amounts of all involved proteins 
individual interactions between receptor subunits were probed by solid phase detection in 
terms of stoichiometry, dynamics and binding site identification. By co-immobilizing ifnar1-EC 
and ifnar2-EC on lipid bilayers ternary complex formation with respect to stabilization and 
architecture was investigated. Finally a binding mechanism with ifnar1 as a key element 
explaining differential signaling was proposed. 
 
7.1  Expression, purification and biochemical characterization  
The expression and purification strategy applied for ifnar2-EC and IFNα2, i.e. 
denaturation, reduction and refolding, did not work for ifnar1-EC. Also fusion to MBP and 
expression in different E. coli strains with an oxidizing cytoplasm did not lead to properly 
folded protein. Secretion of ifnar1-EC into E. coli periplasm ended up with monomeric ifnar1-
EC, but low yield and stability supported the decision to choose an alternative strategy. Since 
expression in P. pastoris did also not significantly increase yield or stability (personal 
communication with from Robert Arduini), Sf9 insect cells were chosen as expression host. 
In this work a novel expression strategy for ifnar1-EC in insect cells was successfully 
established. By combining the advantages of genetic engineering in baculovirus with the 
processing machinery of Sf9 secretion pathway, an efficient expression system for ifnar1-EC 
was developed. The yield of ~10 mg/l cell culture was an increase by factor 200 compared to 
E. coli periplasm. The glycosylation was demonstrated to be essential for protein stability, 
whereas ifnar1-EC from E. coli periplasm precipitated either during expression or purification. 
In contrast to P. pastoris [63] glycosylation in Sf9 was defined, which enabled a comfortable 
handling of ifnar1-EC, because deglycosylation was not necessary. Also successful 
formation of disulfide bonds as expected for cytokine receptor domains was confirmed.  
In order to localize binding sites and to investigate complex architecture, several 
ifnar1-EC sub-fragments, mutants and chimeras were expressed. All sub-fragments were 
confirmed to be properly folded like the wild-type, confirming independent folding of the Ig-
like domains. Probably the chosen cutting sites between the predicted Ig-like domains led to 
folded proteins with no hydrophobic areas causing aggregation. Also the position of the his-
tag did not seem to influence expression and folding, indicating the localization of the protein 
termini at the surface. Like ifnar1-EC all sub-fragments and constructs had disulfide bonds 
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and were glycosylated. By comparing the molecular masses of different sub-fragments the 
predicted 9 glycosylation sites were probable. 
In SEC analysis H10-SD123 and SD234-H10 differed in size before deglycosylation, 
but the shift in the apparent molecular weight was also reproducible for the deglycosylated 
proteins. These results indicated a different structural arrangement of 3 Ig-like domains of 
each terminus. It seems that SD1, 2 and 3 were organized in a more stretched manner than 
SD2, 3 and 4, a first sign for a non-symmetrical structural arrangement of the sub-domains. 
This was underlined by comparable observations with SD12 and SD34, indicating the non-
symmetrical arrangement of these to potential CBMs. 
Ifnar1-EC mutants were also expressed and purified in yields comparable to the wild-
type protein. An exception was W250A. This residue may play an important role in structure 
integrity. Interestingly mutants with an exchanged SD4 showed very different properties. 
SD123-IL10R2D2 was > 90 % aggregated, but by exchanging two special sets of residues 
yield and stability were completely restored (V1V2). This observation indicated that these two 
sets of amino acids were important for a proper folding of SD4. The dimerization of SD123-
LRD2 was probably mediated by a free cysteine in LRD2. However, despite dimerization 
SD123-LRD2 was immobilized and still active. Thus, expression of ifnar1-EC in Sf9 was 
proved to be a powerful tool for the preparation of ifnar1-EC variants and possibly other 
cytokine receptors.  
 
7.2  Dissection of interferon receptor assembling 
One major challenge was to dissect the individual contributions of the different 
interactions between ifnar1, ifnar2 and IFNs involved in formation of a signaling complex. For 
the first time, kinetics and thermodynamics of ifnar1-EC ligand binding was quantitatively 
investigated in vitro. Ifnar1 was clearly identified as the low affinity receptor component in 
ifnar. The association constant KA (1/KD) towards IFNα2 as well as IFNβ was three orders of 
magnitude lower compared to ifnar2. This confirmed a two-step binding process. In the first 
step ifnar2 binds to IFN, in the second step ifnar1 binding mediates complex formation. 
A striking observation was the drastically higher affinity of IFNβ towards both ifnar1 
and ifnar2 compared to IFNα2, monitored by RIfS as well as SEC. These results are in 
agreement with the fact, that the complex of ifnar1 and ifnar2 with IFNβ is stable in immuno-
precipitation, while it is not with IFNα2 [71, 73]. These differences in affinity towards ifnar1 
and ifnar2 also mean that IFNβ engages ifnar more efficient than IFNα2 does. For IFNα2 
mutants a clear correlation between affinity towards ifnar2-EC and anti-viral activity has been 
shown [80]. The antiviral activity of IFNβ is only by a factor of 2-4 higher than for IFNα2, and 
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not by orders of magnitude. However, saturation of activity has been also observed for GH 
with substantially enhanced binding affinities [18]. While the reason for this saturation is not 
fully clear, it is very well possible, that this effect is different for different types of responses. 
Differential efficiencies in the engagement of ifnar1 (and ifnar2) by IFNβ compared to IFNα2 
could then explain that in contrast to IFNα, IFNβ shows additional gene activation at lower 
(i.e. physiological) concentrations, while at higher concentration similar activities were 
observed [75]. Although cross-linking of the receptor components by specific interactions 
with different sites on the ligand is still the basic paradigm for how signal activation is 
induced, the mode of how this is achieved is currently under controversial debate. Probably 
even different modes apply for different systems. Increasingly, pre-association of the 
receptor chains has been postulated [28], [35], and their activation by conformational 
changes induced by the ligand. In the case of class I cytokine receptors, stem-stem contacts 
between the membrane-proximal, extracellular receptor domains have been shown to be 
important for the formation of stable ternary complexes, namely growth hormone receptor 
(GHR) [15],[103], interleukin-4 receptor [104] and interleukin-6 receptor [105]. Though the 
affinities of such receptor-receptor interactions have not been quantified yet, cooperative 
stabilization by inter-receptor and ligand-receptor contacts was clearly shown. Gel filtration 
assays carried out with recombinant ifnar1-EC, ifnar2-EC and IFNβ [63] indicated a similar 
scenario for the type I interferon receptor. For both IFNα2 and IFNβ, such cooperative 
interaction could be clearly excluded, as a significant difference in the affinity of the 
interaction of ifnar1-EC with IFNα2 alone and in complex with ifnar2 was not detected. 
Furthermore, no direct interaction between ifnar1 and ifnar2 could be detected, neither by 
solid phase detection, nor by FRAP. These results suggest a different mode of interaction for 
this member of the class II cytokine receptor superfamily compared to the members class I 
family mentioned above. This is in good agreement with the observation that the binding site 
for IFNα is not located on the membrane-proximal tandem Ig-like domains, but at the hinge 
between the two extracellular tandem Ig-like domains [82, 84]. 
Characterization of the binding site of human ifnar1 in vivo has been hampered by the 
extremely low affinity towards its ligands: the high-affinity interaction with ifnar2 dominates 
binding to the cellular receptor, while binding to ifnar1 alone is too transient to be 
appropriately detectable. Therefore, most information about ligand recognition by ifnar1 stem 
from experiments with bovine ifnar1-EC, which binds human IFNα´s with much higher affinity 
[83, 84]. Here, for the first time ligand binding to different sub-fragments of human ifnar1-EC 
was analyzed in vitro in order to better define ligand recognition. The architecture of ifnar1-
EC with its four Ig-like domains suggests potentially two cytokine binding modules. The sub-
fragments addressed the question of Ig-like domains´ spatial arrangement  
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By direct ligand binding assays, it was clearly shown that these potential CBMs, SD12 
and SD34, separately do neither interact with IFNα2 nor with IFNβ. Even when co-
immobilized on a fluid support, which allowed lateral rearrangements, the binding site was 
not restored. It was concluded that the linkage between SD2 and SD3 is absolutely critical for 
ligand binding. Out of the two sub-fragments containing three Ig-like domains – i.e. with an 
intact linkage between SD2 and SD3 – only SD123 retained its ligand binding activity. These 
results have an interesting relationship to the observations in SEC. The differences in the 
apparent molecular size indicated an asymmetric architecture of the 4 Ig-like domains of 
ifnar1 and not simply two, linked symmetric CBMs.  
No differences in terms of sub-domains required for ligand recognition were found for 
IFNα2 and IFNβ, which have been suggested to bind to different epitopes on ifnar1 [82]. 
Direct competition experiments could show that the binding sites of IFNα2 and IFNβ are at 
least overlapping, if not congruent. This was also supported by site directed mutagenesis, 
since all involved residues affected the interaction with IFNα2-HEQ as well as IFNβ. All these 
studies suggest that ifnar1 is recognized in a very similar manner by these IFNs. 
 
7.3  Complex formation on lipid bilayers 
For characterizing the role of individual interactions for ligand-induced receptor 
assembly, the ternary complex formation with the extracellular receptors tethered in an 
oriented fashion on supported membranes was investigated. Based on combined 
fluorescence and label-free detection receptor assembling was studied on a mechanistic 
level, which may help to explain how differences in receptor engagement by IFNα2 and IFNβ 
results in differential signaling. 
A very stable ternary complex was observed at high surface concentrations of ifnar1 
and ifnar2. Compared to the binding to ifnar2 alone IFNα2 binding was extremely stable, 
decreasing the apparent kd by factor 200. With respect to the very low affinity of ifnar1-EC 
toward IFNα2 and the transient interaction of these proteins, the mode of stabilization was 
investigated in detail. Ternary complex stability was demonstrated to be dependent on 
receptor surface concentration. This surface concentration dependency as well as the 
possibility to exchange the bound ligand with much faster rates than the apparent 
dissociation rate constant confirmed kinetic rather than static stabilization of the complex. In 
combination with the fact that interactions between ifnar2-EC and ifnar1-EC were not 
observed, a two-step assembling mechanism was suggested (Figure 58): After binding of 
IFN to ifnar2 (k1), ifnar1 transiently associates to the complex. Owing to the low life-time of 
the IFNα2-ifnar1 interaction, the complex dissociates (k-2) and re-associates (k2) in a fast 
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manner (on a second scale). At lower receptor surface concentrations the re-association 
kinetics is slowed down and kinetic stabilization is diminished, leading to faster dissociation 
of IFN (k-1). 
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Figure 58  Model of two-step formation and kinetic stabilization of the ternary complex upon IFN 
binding  
Depending on the receptor surface concentrations only part of the ligand bound is 
involved in the ternary complex. The fraction is defined by the equilibrium dissociation 
constant for the interaction of ifnar2-EC-IFN complex with ifnar1-EC on the surface 
(K2 = k-2/k2). From cellular interaction assays, a 10-20-times decrease in KD due to ifnar1 has 
been observed for IFNα2. Taking this into account and furthermore assuming that the 
biophysical environment is in principle mimicked appropriately, these results have several 
important implications for the mechanism of receptor assembling: (i) The formation of a 
stable pre-formed receptor-complex by interactions mediated via the extracellular domains 
as suggested for other receptors [26], [28], [106] is very unlikely; (ii) the receptor components 
are in some way co-localized on the surface of the plasma membrane, as random distribution 
of several hundred receptors on the plasma membrane would not be sufficient for gaining 10-
20-times increased stability. This is in line with the observation that ifnar1 and ifnar2 are 
located in caveolae [107]; (iii) different receptor concentrations not only lead to different 
apparent binding affinities, but also different fractions of IFN involved in the ternary complex.  
As a consequence of this model ifnar1 can explained as the limiting factor for 
complex formation, which controls the efficiency of complex formation by the variation of k2 
(K2). This hypothesis is also supported by the experiments elucidating the role of SD4. This 
sub-domain does not seem to play a significant role for ligand recognition and is also not 
required for ternary complex formation with ifnar2-EC. In cells, however, no high affinity 
ligand binding site was observed in the absence of SD4 or when it was exchanged by a 
corresponding domain of homologous cytokine receptors. In addition the analysis of these 
constructs  in vitro indicated that ternary complex formation is still possible, although 
recruitment efficiency is substantially impaired if SD4 is absent or exchanged. The decrease 
of ligand binding stability observed for N-terminally attached or impaired ifnar1 constructs 
reflect an increase in K2 (decrease in k2). This drop in surface binding affinity can be ascribed 
to a decrease in the surface association rate constant, which was shown to be enhanced on 
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the membrane in terms of successful collisions [100]. Non-optimal orientation of the ligand 
binding site of ifnar1 on the membrane probably reduces the collision efficiency, and thus 
reduces the surface association rate constant and the surface affinity constant.  
One of the key questions is how differential signaling of IFNα2 and IFNβ is encoded 
in the mechanism of receptor assembly. IFNα2 and IFNβ neither differ in the stoichiometry of 
their individual interactions with the receptor subunits nor in the stoichiometry of the 
components in the ternary complex. It was also shown that both IFNs are recognized via the 
same binding domains and residues. The only major difference between these two IFNs was 
the affinity towards ifnar1, which was ~ 100-fold higher for IFNβ than for IFNα2. Results 
indicated that ifnar1 recruitment is likely to be the limiting factor in IFN signal activation. This 
leads to the hypothesis, that differential signaling is encoded in the affinity of ifnar1 towards 
different IFNs. As one possibility, different signaling pathways could require different 
amounts of ternary complexes. It is also probable, that for several pathways a certain 
complex stability is required. In case of IFNα2 and IFNβ, the antiviral and the antproliferative 
activity are examples for differential signaling. For antiviral activity lower concentrations of 
ternary complex are required than for antiproliferative activity. Since IFNβ has a higher 
affinity towards ifnar1, a higher absolute number of complexes per cell are expected 
compared to IFNα2, which explains a higher antiproliferative effect of IFNβ. IFNβ was also 
demonstrated to induce signaling in cancer cells with a reduced ifnar1 level, but IFNα2 had 
no effect [108]. Affinity of individual IFNs toward ifnar1 seems to be an important element of 
differential signal activation. Ifnar1 surface concentration was also demonstrated to be 
correlated with complex formation efficiency. Differences between individual cell types in IFN 
response could be explained by the variation of ifnar1 surface concentration. Cells could 
control their sensitivity to different IFNs by their ifnar1 surface expression level. As a 
conclusion of this work ifnar1 was proposed to be the key element in IFN mediated 
differential signaling. 
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7.4 Outlook 
One aspect which has not been taken into account so far is the role of the trans-
membrane domains. It is possible that they have an effect on complex formation. Therefore 
ifnar1 and ifnar2 carrying the trans-membrane domains have to be expressed and 
reconstituted. By comparison with the established assays on chelator surfaces the 
contributions of these domains could be elucidated. 
To achieve a more detailed picture of the complex architecture, a more detailed view 
to the structure of ifnar1-EC as well as the ternary complex is necessary. By applying the 
knowledge of protein immobilization on lipid bilayers 2D crystallization would be the first step 
in structure biology. With this technique the arrangement of the four ifnar1-EC sub-domains 
with respect to the sub-domains of ifnar2-EC can be estimated. The 3D-analsis by X-ray 
crystallography is then the next challenging project, but in case of success the structure of 
the ternary complex would be a milestone in cytokine receptor research. Also FRET studies 
in solution and on surfaces would generate additional information about conformational 
changes during complex assembly. 
For the identification of additional residues involved in ligand binding, the site directed 
mutagenesis of ifnar1-EC has to be continued. By double mutant cycle analysis interaction 
pairs can be identified and their binding enthalpy can be determined. Also the role of 
individual residues in the formation of the ternary complex has still to be investigated. 
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8 Abbreviations   
2-5A-sythase 2-5-oligoadenylat-systhase 
AcNPV  Autographa californica nuclear polyhedrosis virus 
ATP adenosintriphosphate 
bp base  pair(s) 
BL bilayer 
BSA  bovine serum albumin 
CD circular  dichroism 
CIAP  calf intestine alkaline phosphatase 
CP cytoplasmic  domain 
CSF colony-stimulating  factor 
dNTP desoxy-nucleotidetriphosphate 
DT double  tagged 
DTT dithiothreitol 
E. coli  Escherichia coli 
EC extracellular  domain 
EGF  epidermal growth factor 
EPO erythropoietin 
FCS   fetal calf serum 
FRAP   fluorescence recovery after photobleaching 
G-CSF  granulocyte colony-stimulating factor 
GH growth  hormone 
GM-CSF  granulocyte and macrophage colony-stimulating factor 
H10 deca-histidine-tag 
HBS  Hepes buffer saline 
HSA  human serum albumin 
IDA Iodo-diacetic  acid 
IFN interferon   
ifnar  interferon alpha receptor 
ifnar1  type I interferon receptor subunit 1 
ifnar2  type I interferon receptor subunit 2 
Ig immunoglobulin 
IL interleukin 
IL-10R2D2  interleukin-10 receptor domain 2 
IMAC  immobilized metal affinity chromatography 
ISGF  interferon-stimulated gene activating factor 
ISRE  interferon-stimulated regulatory elements 
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JAK Janus-activated  kinase 
ka association rate constant 
kDa kilo  Dalton 
KD dissociation constant 
kd dissociation rate constant 
LCR ligase  chain  reaction 
LRD2  lambda receptor domain 2 
MBP  maltose binding protein 
MHC  major histocompatibility complex 
NAD nicotinamidadeninetriphosphate 
NMR  nuclear magnetic resonance 
NTA nitroso-tetra-acetic  acid 
P. pastoris  Picchia pastoris 
PAGE polyacrylamide  gelelectrophoresis 
PBS(T)  phosphate buffer saline (Tween) 
PCR polymerase  chain  reaction 
PI-3-K phospatidyl-inositol-3-kinase 
PKR  protein kinase R 
Pwo Pyrococcus  woesei 
Rif(S)  reflectance interference spectroscopy 
RNA ribonucleic  acis 
rpm rounds  per  minute 
SD sub-domain 
SDS sodiumdodecylsulfate 
SEC  size exclusion chromatography 
Sf9  Spodoptera frugiperda 9 
SOPC stearoyl-oleoyl-phosphatidycholine 
STAT  signal transducer and activator of transcription 
TAP  transporter associated with antigen processing 
Taq Thermophilus  aquaticus 
TBS(T)  Tris buffer saline (Tween) 
TIRFS  total internal reflection fluorescence spectroscopy 
tl tag-less 
TMD transmembrane  domain 
TNF  tumor necrosis factor 
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